Check for updates

OPEN ACCESS

EDITED BY Lisa N. Sharwood, University of New South Wales, Australia

REVIEWED BY Alina Gonzalez-Quevedo, Instituto de Neurología y Neurocirugía, La Habana, Cuba Yong-Bo Zheng, Peking University Sixth Hospital, China Vikas Dhikav, Indian Council of Medical Research (ICMR), India

*CORRESPONDENCE Juan Li 785939016@qq.com Rongjiang Jin © cdzyydxjrj@126.com Wei Jiang © jiangwei202301@163.com

RECEIVED 02 August 2023 ACCEPTED 31 December 2023 PUBLISHED 13 February 2024

CITATION

Xie C, Zhong D, Zhang Y, Liu X, Zhang L, Luo X, Gong Y, Jiang W, Jin R and Li J (2024) Prevalence and risk factors of cognitive impairment in Chinese patients with hypertension: a systematic review and meta-analysis. *Front. Neurol.* 14:1271437. doi: 10.3389/fneur.2023.1271437

COPYRIGHT

© 2024 Xie, Zhong, Zhang, Liu, Zhang, Luo, Gong, Jiang, Jin and Li. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Prevalence and risk factors of cognitive impairment in Chinese patients with hypertension: a systematic review and meta-analysis

Cheng Xie¹, Dongling Zhong¹, Yue Zhang¹, Xiaobo Liu¹, Lili Zhang², Xiao Luo¹, Yimeng Gong¹, Wei Jiang³*, Rongjiang Jin¹* and Juan Li^{1,4}*

¹School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ²First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ³Department of Orthopedics, Pingshan County Hospital of Traditional Chinese Medicine, Yibing, China, ⁴Affiliated Sichuan Provincial Rehabilitation Hospital of Chengdu University of Traditional Chinese Medicine and Sichuan Provincial BAYI Rehabilitation Center, Chengdu, China

Background: Cognitive impairment is prevalent in Chinese patients with hypertension; however, current evidence on prevalence and risk factors is required to be synthesized.

Objectives: This systematic review and meta-analysis aimed to evaluate the prevalence and risk factors of cognitive impairment in Chinese patients with hypertension.

Methods: Two reviewers independently searched PubMed, Web of Science, Embase, The Cochrane Library, CNKI, CBM, the Wanfang database, and the VIP database from their inception to 7 June 2023. The gray literature and the reference lists of the included studies were also retrieved manually. Moreover, we also independently performed the eligibility screening, data extraction, and data synthesis. The primary outcome was the prevalence of cognitive impairment in Chinese patients with hypertension, and the secondary outcomes were the risk factors for cognitive impairment in patients with hypertension. R (version 4.0.3) was used for data synthesis.

Results: In total, 82 studies involving 53,623 patients with hypertension were included in this meta-analysis. The pooled prevalence of cognitive impairment in patients with hypertension was 37.6% (95% CI: 33.2–42.2%). A total of 12 risk factors, including advanced age (r=-0.34, 95% CI: -0.45, -0.21), female sex (OR=1.15, 95% CI: 1.01-1.32), BMI>24 Kg/m² (OR=1.76, 95% CI: 1.04-3.00), lower educational level (OR=2.01, 95% CI: 1.10-3.67), single status (OR=1.63, 95% CI: 1.32-2.02), complications with diabetes (OR=1.44, 95% CI: 1.14-1.80), coronary heart disease (OR=1.49, 95% CI: 1.12-1.97), higher stage of hypertension [stage 3 vs. stage 1, OR=3.08, 95% CI: 1.82-5.22; stage 2 vs. stage 1, OR=1.83, 95% CI: 1.29-2.60], no regular physical activity (OR=0.40, 95% CI: 0.21-0.77), higher levels of systolic blood pressure (r=-0.25, 95% CI: -0.42, -0.08), Hcy (r=-0.39, 95% CI: -0.63, -0.09), and IL-6 (r=-0.26, 95% CI: -0.48, -0.02) were detected.

Conclusion: Cognitive impairment is prevalent in Chinese patients with hypertension, and the increased prevalence was associated with several demographic characteristics, complicated disease, no regular physical activity, worse hypertension status (higher stages and SBP), and high levels of biomarkers. Therefore, more attention should be paid to the early identification and treatment

of patients with hypertension who are at high risk for cognitive impairment in clinical practice. In addition, relevant risk factors should be controlled to reduce the incidence of cognitive impairment.

Systematic review registration: http://www.crd.york.ac.uk/PROSPERO, identifier [CRD42023410437].

KEYWORDS

cognitive impairment, hypertension, prevalence, risk factors, China, meta

1 Introduction

Hypertension is characterized by sustained blood pressure (BP) elevations and is associated with target organ damage and an increased risk of cardiovascular disease (CVD) (1, 2). According to a recent report (3), as of 2023 there were approximately 256.7 million adults with hypertension in China, accounting for nearly one-fifth of the 1.3 billion patients worldwide. However, only 16% of them had their BP under control. Additionally, the Chinese age-standardized prevalence of hypertension has increased from 24.7 to 27% in recent years (4), of which stage 2 and higher hypertension accounted for approximately 41% (5).

Cognitive impairment is a common complication of hypertension, usually consisting of a decline in memory, attention, visuospatial abilities, and executive functions (6). Cognitive impairment is the main cause of disability in the elderly, affecting nearly 50 million individuals worldwide, and is expected to increase to more than 130 million individuals by 2050 (7). According to the reports, apart from age, hypertension is the most important risk factor for cerebrovascular pathology, which increases the incidence of cognitive impairment and accelerates the transition to dementia (6, 8, 9). Several studies have concluded that the risk of cognitive dysfunction is increased to 40% in patients with hypertension, as opposed to those without hypertension (10-12). In addition, hypertension complicated with cognitive impairment was associated with a higher risk of depression (13), motor dysfunction (14), poor quality of life (14), and a higher incidence of falls and syncope (15), which contributed to a high mortality rate. According to the World Health Organization (WHO), hypertension complicated with cognitive impairment is a growing public health concern, especially in developing countries (16).

A previous meta-analysis (17) evaluated the global prevalence of mild cognitive impairment (MCI) in patients with hypertension. However, the prevalence of moderate and severe cognitive impairment was unclear. Furthermore, the risk factors had not been investigated yet. Considering the high prevalence and poor control rate in China, exploration of the prevalence and risk factors of cognitive impairment in Chinese patients with hypertension would be beneficial for developing effective management strategies. Therefore, the present study aimed to perform quantitative syntheses of the prevalence and investigate the risk factors of cognitive impairment in Chinese patients with hypertension. Moreover, association analysis was conducted to explore the relationship between potential risk factors and cognitive function. The results of this systematic review and meta-analysis would provide current evidence for clinicians and policymakers in the management of hypertension complicated by cognitive impairment.

2 Methods

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (18), and the study protocol was registered with PROSPERO (CRD: 42023410437). The PRISMA checklist is shown in Supplementary Table 1.

2.1 Search strategy

Two reviewers (X Luo and YM Gong) independently searched PubMed, Web of Science, Embase, The Cochrane Library, CNKI, CBM, the Wanfang database, and the VIP database from their inception to 7 June 2023. Search strategies were developed using a combination of Medical Subject Headings (MeSH) and free text words related to hypertension and cognitive impairment. The gray literature and reference lists of the included studies were manually retrieved. In addition, experts in relevant fields were consulted for other possible studies. The detailed search strategies are shown in Supplementary Table 2.

2.2 Inclusion criteria

The inclusion criteria for this study were: (1) observational studies, including cross-sectional, cohort, and case–control studies, without the limitation of publication year; (2) Chinese population aged over 18 years without limitation of region and sex; (3) the prevalence of cognitive impairment in Chinese patients with hypertension was reported or could be calculated; (4) hypertension was diagnosed according to the WHO (19) or the 2010 Chinese guidelines for the treatment of hypertension (20), of which SBP \geq 140 mmHg, and/or DBP \geq 90 mmHg; (5) cognitive impairment was evaluated by recognized assessment tools with good reliability and validity; (6) the language of the published studies was limited to English or Chinese.

2.3 Exclusion criteria

The exclusion criteria for this study were: (1) the materials found being reviews, letters, conference reports, or protocols; (2) patients with hypertension complicated by stroke, Parkinson's disease, traumatic brain injury, or other diseases that affected cognitive function; (3) the time and regions of the investigation were not reported; (4) overlapping publications; (5) the data were unavailable or could not be retrieved using different approaches.

2.4 Study selection

The retrieved records were imported into Endnote software (version X9) and the duplicate records were removed. Then, two independent reviewers (C Xie and DL Zhong) screened the titles and abstracts of the remaining records to exclude irrelevant literature. Subsequently, the full texts of the remaining studies were reviewed to assess eligibility. Any disagreements were arbitrated by a third reviewer (XB Liu).

2.5 Data extraction

Two reviewers (C Xie and DL Zhong) independently extracted the data using a pre-designed form. The following details were extracted: (1) the basic characteristics of the study: the first author, publication year, study site, and sample size; (2) the details of the participants, such as age, sex, body weight status, educational level, family status, etc.; (3) the assessment tools for cognitive impairment; (4) the outcomes: the primary outcome was the prevalence of cognitive impairment in patients with hypertension, while the secondary outcomes were the risk factors of cognitive impairment in patients with hypertension. The extracted data were cross-checked by the two reviewers. Any discrepancies were resolved through team discussion.

2.6 Risk of bias assessment

The risk of bias in the included studies was assessed by two independent reviewers (Y Zhang and LL Zhang) using the tool developed by Hoy et al. (21) to assess the risk of bias in epidemiologic studies. The tool comprises 10 items and a summary assessment: items 1–4 describe the external validity, including selection and nonresponse bias; items 5–10 assess the internal validity, including measurement and analysis bias. Each item is rated as "low risk" or "high risk" and the overall risk of bias is dependent on the number of "low risk" items. An overall low risk of bias is defined as 9–10 items with "low risk"; an overall moderate risk of bias is defined as 6–8 items with "low risk"; and an overall high risk of bias is defined as less than 5 items with "low risk."

2.7 Statistical analysis

Data synthesis was performed using the meta packages of R (version 4.0.3). Before pooling the prevalence, we conducted normality tests based on logit-transformed proportions. The proportion of cognitive impairment in patients with hypertension was synthesized to calculate a pooled prevalence with a 95% confidence interval (CI). When analyzing the risk factors, the odds ratio (OR) was chosen as the effect size for the categorical variables (sex, body weight status, educational level, etc.), while the Pearson r correlation coefficient was chosen for continuous variables (age, level of SBP and DBP, etc.) (22). Heterogeneity was assessed by the Cochran Q test and the statistical value of I^2 , and it was considered significant

heterogeneity if $I^2 \ge 50\%$ and p < 0.1, while $I^2 \le 50\%$, p > 0.1 meant nonsignificant heterogeneity. The random effects model was selected for the synthesis of results.

2.8 Subgroup analysis

Subgroup analysis was conducted according to the following aspects: (1) basic characteristics of the participants: sex (male, female subjects), body weight status (BMI ≤ 24 Kg/m², >24 Kg/m²), educational level (primary school and below, middle school and above), family status (married, single); (2) recruitment source (community-based, hospitalized); (3) condition of the disease: duration of hypertension (<5 years, 5–10 years, >10 years), complications [diabetes, coronary heart disease (CHD)], classification of hypertension (stage 1, stage 2, stage 3); severity of cognitive impairment (mild, moderate, severe); (4) lifestyle: smoking and drinking, and engagement in regular physical activity; (5) assessment tools for cognitive impairment; (6) study design (cross-sectional studies, cohort studies).

2.9 Meta-regression

Univariable meta-regression analysis was conducted to explore the source of heterogeneity from the following characteristics: study period (before 2010, between 2010 and 2015, between 2015 and 2020, after 2020); regions (Nationwide, Central China, East China, North China, Northeast China, Northwest China, South China, Southwest China), recruitment source (community-based, hospitalized), study design (cross-sectional studies, cohort studies), assessment tools for cognitive impairment, sample size (0–100, 100–500, 500–1,000, >1,000), and risk of bias (low, moderate, high).

2.10 Sensitivity analysis

A sensitivity analysis was conducted to verify the stability of the main findings by eliminating the included studies one by one.


2.11 Publication bias

A funnel plot and *Egger's* test were performed to assess the publication bias. The trim and fill method was used to verify the stability in cases of existing publication bias.

2.12 Certainty of evidence

The certainty of the evidence was assessed according to the GRADE guidelines using the GRADEpro GDT.¹ For the primary outcome, we assessed the following five domains: limitations, inconsistency, indirectness, imprecision, and publication bias. The certainty of the evidence was reported in four categories, including

¹ http://gradepro.org/



high, moderate, low, and very low. Observational studies were classified as low-certainty evidence.

3 Results

3.1 Study selection

A total of 3,294 records were identified from electronic databases. After removing 787 duplicates, 2,293 irrelevant records were excluded by screening the titles and abstracts. The full texts of the remaining 197 records were reviewed and 82 studies were finally included. The list of excluded studies with reasons is presented in Supplementary Table 3. The flow chart is shown in Figure 1.

3.2 Study characteristics

The basic characteristics of the included studies are summarized in Supplementary Table 4. A total of 53,623 patients with hypertension were included in this meta-analysis. Regarding the study regions, 3 studies were from the nationwide survey, 8 studies were from Central China, 21 studies were from East China, 21 studies were from North China, 1 study was from South China, 7 studies were from Northeast China, 13 studies were from Northwest China, and 8 studies were from Southwest China. The sample size ranged from 55 to 11,270 patients, and the mean age of the patients ranged from 38 to 93 years. The Mini-mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Peterson, Clinical Dementia Rating, Clock Drawing Test, AD-8, Basic Cognitive Aptitude Tests, and clinical memory scale were used to assess cognitive function.

3.3 Risk of bias

The risk of bias in the included studies is described in Supplementary Table 5. In terms of the representation of the target population, four studies were judged as low risk, while the remaining studies were assessed as high risk because the target population could not represent the national population. The sampling frame of 15 studies was close to the target population, so they were rated as low risk, and the remaining studies were rated as high risk. Regarding the

random selection of the sample, 15 studies selected the samples randomly and were assessed as low risk, while the remaining 67 studies failed to implement randomization and were considered high risk. Regarding the data collected directly from subjects, Luo et al. (23) collected these indirectly and assessed them as high risk, while the remaining 81 studies directly synthesized the data and were rated as low risk. With regard to the domains of proceeded minimal non-response bias, appropriate case definition, validated measure, consistent mode of data collection, appropriate length of the shortest prevalence period, and correct calculation of prevalence, all included studies were assessed as low risk. In summary, the overall risk of bias in 15 studies was rated as low, while 67 studies were rated as having a moderate risk of bias.

3.4 Prevalence of cognitive impairment in Chinese patients with hypertension

Based on 82 studies involving 53,623 patients with hypertension, the pooled overall prevalence of cognitive impairment in the subjects was 37.6% (95% CI: 33.2-42.2%, $I^2 = 98\%$, p < 0.01; Figure 2). Regarding the severity of cognitive impairment, the prevalence of MCI in Chinese patients with hypertension was 37.0% $(95\% \text{ CI: } 29.6-45.1\%, I^2 = 99\%, p < 0.01)$, which was higher than the prevalence of moderate (23.7, 95% CI: 14.5–36.3%, $I^2 = 90\%$, p < 0.01) and severe cognitive impairment (11.7, 95% CI: 3.7–31.6%, $I^2 = 93\%$, p < 0.01; Supplementary Figure 1). In terms of the assessment tools for cognitive impairment, the prevalence of cognitive impairment in Chinese patients with hypertension was higher on the basis of MoCA (48.7, 95% CI: 40.0–57.5%, $I^2 = 97\%$, p < 0.01) than that based on MMSE + MoCA (48.1, 95% CI: 41.4– 54.9%, *I*² = 91%, *p* < 0.01) and MMSE (32.0, 95% CI: 26.9–37.6%, $I^2 = 98\%$, p < 0.01; Supplementary Figure 2). As for recruitment source, the prevalence of cognitive impairment in hospitalized patients with hypertension (40.8, 95%CI: 36.0–45.9%, $I^2 = 96\%$, p < 0.01) was higher than that in community-based patients (26.8, 95% CI: 19.1–36.1%, *I*² = 99%, *p* < 0.01; Supplementary Figure 3). With respect to the study design, the prevalence of cognitive impairment in patients with hypertension from cross-sectional studies (40.8, 95% CI: 36.1–45.7%, *I*² = 98%, *p* < 0.01) was higher than that in cohort studies (25.9, 95% CI, 18.3–35.2%, $I^2 = 99\%$, *p* < 0.01; Supplementary Figure 4).

3.5 Risk factors for cognitive impairment in Chinese patients with hypertension

The detailed results of the risk factors are summarized in Table 1.

3.5.1 Sex

A total of 49 studies included 13,695 male and 15,974 female patients with hypertension. The results indicated that female patients with hypertension had a higher prevalence of cognitive impairment (40.3, 95% CI: 34.9–45.9%, $I^2 = 97\%$, p < 0.01) than the male patients (37.1, 95% CI: 31.6–43.0%, $I^2 = 97\%$, p < 0.01; Supplementary Figure 5A). The OR for female subjects vs. male subjects was 1.15 (95% CI: 1.01–1.32, $I^2 = 91\%$, p < 0.01; Supplementary Figure 5B).

3.5.2 Body weight status

Five studies reported the prevalence of cognitive impairment in patients with hypertension based on BMI >24 Kg/m² (2,859 participants) and BMI \leq 24 Kg/m² (4,532 participants). The patients with hypertension whose BMI > 24 Kg/m² had a higher prevalence of cognitive impairment (46.0, 95% CI: 36.5–55.7%, I^2 =96%, p < 0.01) than those whose BMI \leq 24 Kg/m² (33.4, 95% CI: 24.3–43.8%, I^2 =78%, p < 0.01; Supplementary Figure 6A). The OR between patients with BMI >24 Kg/m² and those with BMI \leq 24 Kg/m² was 1.76 (95% CI: 1.04–3.00, I^2 =91%, p < 0.01; Supplementary Figure 6B).

3.5.3 Educational level

According to the educational level, 18 studies with 4,258 patients in primary school and below, and 5,829 patients in middle school and above with hypertension were included. The prevalence of cognitive impairment was higher in patients with hypertension in primary school and below (36.5, 95% CI: 26.1–48.2%, $I^2 = 97\%$, p < 0.01) than in patients in middle school and above (26.9, 95% CI: 17.6–38.8%, $I^2 = 96\%$, p < 0.01; Supplementary Figure 7A). The OR of patients with hypertension in primary school and below compared with those in middle school and above was 2.01 (95% CI: 1.10–3.67, $I^2 = 85\%$, p < 0.01; Supplementary Figure 7B).

3.5.4 Family status

In total, nine studies reported that 10,643 patients with hypertension were married and 2,822 patients were single. Single patients with hypertension showed a higher prevalence of cognitive impairment (31.7, 95% CI: 21.2–44.6%, $I^2 = 97\%$, p < 0.01) than married patients (21.4, 95% CI: 13.4–32.2%, $I^2 = 99\%$, p < 0.01; Supplementary Figure 8A). The OR for the single patients compared with the married patients was 1.63 (95% CI: 1.32–2.02, $I^2 = 61\%$, p < 0.01; Supplementary Figure 8B).

3.5.5 Duration of hypertension

The duration of hypertension was dichotomized into <5 years, 5-10 years, and > 10 years. Among patients with hypertension, the prevalence of cognitive impairment in patients with a duration of hypertension >10 years was 33.5% (95% CI: 17.1–55.1%, $I^2 = 97\%$, p < 0.01), followed by those with a duration of 5–10 years (30.8, 95% CI: 12.1–58.9%, $I^2 = 97\%$, p < 0.01) and <5 years (24.2, 95% CI: 16.5–34.0%, $I^2 = 91\%$, p < 0.01; Supplementary Figure 9A). However, no statistical difference was detected among the three groups (5–10 vs. <5, OR = 1.29, 95% CI: 0.49–3.41, $I^2 = 88\%$, p < 0.01; >10 vs. <5, OR = 1.08, 95% CI: 0.93–1.25, $I^2 = 0\%$, p = 0.33; Supplementary Figures 9B,C).

3.5.6 Diabetes/CHD complications

There were 1,724 patients with hypertension complicated by diabetes and 7,915 patients without diabetes in the 18 included studies. The findings revealed that patients with hypertension complicated with diabetes had a higher prevalence of cognitive impairment (47.8, 95% CI: 38.3–57.4%, I^2 =90%, p <0.01) than those without diabetes (39.9, 95% CI: 31.7–48.7%, I^2 =95%, p <0.01; Supplementary Figure 10A). The OR in those with diabetes compared with those without diabetes was 1.44 (95% CI: 1.14–1.80, I^2 =64%, p <0.01; Supplementary Figure 10B).

A total of 14 studies included 1,197 and 7,459 patients with hypertension complicated with and without CHD, respectively. A

Cheng 2011 Cheng 2011 Cheng 2011 Cheng 2011 Char 2018 Chi 201	1	Study E	Events	Total		Proportion	95%-CI
Chen 2022 6 97 Chang 2011 123 220 Chang 2011 123 220 Chang 2011 123 220 Chang 2011 123 220 Chang 2012 120 20 Chang 2012 120 20 Chang 2012 120 20 Chang 2012 120 20 Chang 2017 1		Cai 2018	41	151		0.272	[0.202: 0.350]
Cheng 2011 123 220 Feng 2018 20 67 Geng 2017 125 23 Geng 2018 2 115 Geng 2018 2 1272 1270 Hz 2019 12 5 23 Hug 2019 25 544 Hz 2013 198 110 Hz 2014 192 2 Hz 2014 192 2 Hz 2015 194 2 Hz 2015 194 2 Hz 2016 194 2 Hz 2016 194 2 Hz 2017 195 23 Hz 2018 194 2 Hz 2018 195 2 Hz 2018 195 2 Hz 2018 195 2 Hz 2018 195 2 Hz 2018 196 2 Hz 2018 2 Hz 2018 196 2 Hz 2018 2			6	97	-		
Chi 2018 8 1 404 Gan 2021 218 133 Gan 2021 218 133 Gan 2021 218 133 Gan 2021 128 122 Heidball 2021 128 122 Heidball 2021 128 122 Huang 2029 265 446 Ju 2013 189 110 Ju 2013 189 110 Ju 2013 189 110 Ju 2013 189 170 Huang 2029 265 446 Ju 2013 189 177 Huang 2029 265 446 Ju 2016 189 229 Huang 2029 266 448 0.577 0.440 0.583 0.237 0.440 0.578 0.583 0.237 0.441 0.583 0.239 0.448 0.577 0.440 0.458 0.383 0.237 0.441 0.583 0.239 0.448 0.577 0.440 0.458 0.383 0.237 0.441 0.583 0.239 0.448 0.577 0.449 0.458 0.383 0.237 0.441 0.458 0.383 0.209 0.448 0.577 0.449 0.458 0.383 0.209 0.448 0.577 0.449 0.458 0.387 0.248 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.459 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.457 0.458 0.458 0.457 0.458 0.457 0.458 0.457 0.458							
Feng 2018 20 87							
Gan 2021 216 113 0.019 0.058.0.058 Gan 2020 107 0.050 0.058.0.058 Gan 2021 131 0.019 0.058.0.058 Gan 2021 135 0.019 0.058.0.058 Gan 2021 135 0.019 0.058.0.059 He 2020 142 0.019 0.058.0.059 He 2020 142 0.019 0.058.0.059 He 2020 142 0.019 0.058.0.059 He 2020 127.2 127.2 0.019 0.058.0.059 He 2020 1019 0.019.0.058 0.039.0.058 0.039.0.058 He 2020 1019 0.019.0.058 0.039.0.048 0.039.0.048 0.039.0.048 Jua 2010 38 197 0.019.0.048 0.043.0.0459 0.043.0.0459 L 2020 10144 0.014 0.014.0.048 0.043.0.0459 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489 0.048.0.0489					*		
Gao 2020 120 120 120 0000 0.552 0.151 0.248 0.151 0.248 0.151 0.248 0.151 0.248 0.151 0.248 0.151 0.248 0.151 0.562 0.552 0.5							
Ge 2009 107 689 # 0.482 0.117 0.533 0.447 Gong 2017 135 233 0.477 0.533 0.444 Gong 2017 135 233 0.477 0.533 0.444 Gong 2017 125 233 0.477 0.542 0.542 0.540 He 2020 14 150 0.422 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242 0.245 0.242					100 - 100 -		
Geng 2018 28 113							
Gong 2017 He 2020 He 2020 H							
$ \begin{array}{c} G_{u} 2019 & 25 & 55 \\ He 2020 & 102 & 202 \\ He 2020 & 64 & 150 \\ He 2020 & 64 & 150 \\ He 2020 & 278 & 272 \\ He 2020 & 278 & 278 \\ He 2021 & 278 & 474 \\ He 2021 & 278 & 474 \\ He 2022 & 973 & 4819 \\ He 2021 & 778 & -478 \\ $							
He 2020 102 202							
He 2020 64 150							
Heichell 2021 2722 11270 0242 10 235 0.250 Huang 2000 265 446 Jin 2018 31 027 0.441 Je 2018 31 027 0.441 Je 2018 31 027 0.441 Je 2018 31 027 0.441 Je 2018 30 027 0.441 Je 2018 30 027 0.441 Je 2018 30 027 0.441 Je 2018 30 028 0.442 Je 2018 30 00 060 0.171 Li 2021 90 144 Li 2011 93 0.066 0.171 Li 2021 93 147 0.460 Je 2018 140 058 0.541 Li 2021 93 146 Li 2021 93 146 Li 2021 93 146 Li 2021 93 146 Li 2022 88 895 Li 2020 19 16 16 23 Li 2021 103 565 Li 2020 171 Li 2022 88 192 Li 2021 88 224 Li 2021 88 124 Li 2019 16 18 0.421 0.031 0.240 0.379 Li 2020 293 162 Li 2020 19 16 187 0.240 Li 2020 15 68 224 Li 2021 189 161 Li 2021 189 161 Li 2021 189 161 Li 2022 93 461 9 Li 2021 189 161 Li 2022 93 461 9 Li 2021 189 161 Li 2020 19 16 177 0.257 Ma 2020 93 162 He 0.576 0.444 0.651 Ma 2021 189 161 Ma 2022 953 461 9 He 0.576 0.444 0.651 Ma 2022 953 461 9 He 0.576 0.448 0.651 Ma 2022 953 461 9 He 0.576 0.448 0.651 Ma 2022 953 461 9 He 0.576 0.448 0.651 Ma 2020 177 177 Ma 2020 16 180 427 0.444 0.440 0.4							
Huang 2009 265 446		Heizhati 2021	2732	11270			
Jin 2016 30 90 Ke 2018 119 220 Ke 2018 119 220 Li 2020 60 146 Li 2021 90 144 Li 2016 43 330 Li 2021 93 135 Li 2021 93 135 Li 2021 93 136 Li 2021 93 136 Li 2020 63 300 Li 2020 63 300 Li 2020 63 300 Li 2020 63 300 Li 2020 63 1300 Li 2020 63 142 Li 2019 16 16 28 Li 2020 17 16 189 346 Li 2020 75 063 Li 2020 75 063 Li 2020 75 069 Ma 2020 93 162 Ma 2021 94 172 Ma 2015 51 115 Fan 2041 443 134 Ma 2022 953 4419 Ma 2022 953 4519 Ma 2021 94 172 Ma 2015 51 115 Fan 2041 443 134 Ma 2022 953 4619 Ma 2022 953 4619 Ma 2022 953 4619 Ma 2021 94 1618 Ma 2022 953 4619 Ma 2022 953 4619 Ma 2022 953 4619 Ma 2022 953 4619 Ma 2021 94 464 1640 Ma 2020 94 164 464 1640 Ma 2020 94 164 464 1640 Ma 2020 958 074 464 1640 1640 1640 Ma 2020 958 074 46		Hu 2013	198	1110	E2		
Jin 2010 38 197 → 0,140,0253 0,453,0586 Li 2020 60 146 0,451,0586 0,453,0586 Li 2021 90 144 0,450 0,453,0586 Li 2016 43 330 → 0,748 0,663,0821 Li 2021 73 138 → 0,748 0,663,0821 Li 2021 16 330 → 0,748 0,663,0821 Li 2021 16 930 → 0,470 0,477		Huang 2009				0.594	[0.547; 0.640]
Ke 2018 119 229							
Li 2020 Li 2021 Li 2017 Li 2017 Li 2021 Li 2022 Li 2021 Li 2022 Li 2015 Li 2022 Li 2016 Li 2022 Li 2021 Li 2022 Li 2018 Li 2021 Li 2021 Li 2021 Li 2021 Li 2021 Li 2022 Li 2018 Li 2022 Li 2018 Li 2021 Li 2022 Li 2018 Li 2022 Li 2018 Li 2021 Li 2022 Li 2018 Li 2022 Li 2019 Li 2022 Li 2019 Li 2022 Li 2019 Li 2021 Li 2021 Li 2021 Li 2021 Li 2021 Li 2021 Li 2021 Li 2021 Li 2022 Li 2018 Li 2022 Li 2018 Li 2021 Li 2022 Li 2016 Li 2017 Li 2016 Li 2017 Li							
Li 2021 90 184 Li 2021 73 33 Li 2021 73 138 Li 2014 628 1386 Li 2014 628 1386 Li 2014 628 1386 Li 2019 116 235 Li 2019 116 236 Li 2019 116 236 Li 2012 88 825 Li 2019 116 236 Li 2012 88 825 Li 2019 116 236 Li 2012 88 234 Li 2018 30 06 Li 2012 88 234 Li 2018 30 06 Li 2015 68 326 Li 2015 68 326 Pin 2022 97 509 Ma 2022 97 509 Ma 2022 97 509 Ma 2022 97 509 Li 2012 194 4172 Ji 10 57 0.227 Ma 2021 194 172 Ji 10 520 241 Ji 10 57 0.227 Ma 2022 97 509 Ma 2022 97 509 Ji 10 520 727 Ma 2021 168 286 Pin 2011 178 Ji 10 520 727 Ma 2022 97 509 Ma 2022 98 34619 Ji 10 530 727 Ma 2021 178 72 Ji 10 530 740 Ji 10 540 740 Ji 10 632 70 740 Ji 10 642 777 Ji 10 642 777							
Li 2016 43 330 77 48 0.0653.0821 Li 2021 73 138 75 76 0.0563.0821 Li 2021 73 138 75 76 0.0563.0821 Li 2020 53 300 77 0.0420.657 Li 2022 88 895 70 442.0547 Li 2022 89 70 45 70 442.0547 Li 2021 88 224 70 440 157 Li 2022 95 812 Li 2021 88 225 70 200 118 105 70 277 Li 2015 89 946 70 750 70 70 70 70 70 70 70 70 70 70 70 70 70							
Li 2017 95 127 0748 [0.632; 0.642; 0.644 Li 2014 628 1386 0748 [0.642; 0.644 Li 2014 628 1386 0748 [0.642; 0.647 Li 2020 53 300 0748 [0.642; 0.647 Li 2021 53 300 0748 [0.642; 0.647 Li 2022 88 895							
Li 2021 73 138 Li 2021 73 138 Li 2020 53 300 Li 2020 53 300 Li 2022 88 895 Li 2021 103 565 Li 2022 85 812 Li 2021 88 224 Li 2018 30 106 Li 2021 88 224 Li 2018 30 106 Li 2020 639 106 Li 2020 648 1042 0.657 Li 2021 88 224 Li 2010 108 036 0367 Li 2020 759 Ma 2015 51 115 Ma 2022 953 4819 Ma 2022 953 60 Ma 2015 1046 400 6050 Ma 2030 10240 027 Ma 2016 1026 502 Ma 2017 1076 1060 506 Ma 202 1000 50 506 Ma 2020					*		
Li 2014 628 1388 0177 0175 0225 Li 2019 116 236 0777 0175 0225 Li 2019 116 236 0777 0175 0225 Li 2012 103 565 078 0142 0420 0567 Li 2022 88 895 0788 0142 0780 0178 0175 0227 Li 2022 88 112 0780 0178 0178 0242 0568 Li 2021 88 234 0413 0780 0178 0178 0242 0568 Li 2021 88 234 0413 0780 0178 0178 0280 0280 0378 0180 0380 0382 Li 2021 88 234 0413 0780 0178 0178 0280 0280 0280 0380 0380 0382 0382 Li 2021 88 181 0780 0178 0178 0280 0280 0280 0280 0280 0280 0280 02							
Li 2020 53 300 Li 2022 88 805 Li 2021 103 565 Li 2021 88 234 Li 2021 88 234 Li 2021 88 234 Li 2021 88 30 106 Li 2022 2434 6413 Li 2021 98 161 Ma 2020 93 162 Ha 2020 93 162 Ha 2022 97 509 Ma 2022 11 68 266 Peng 2010 126 502 Pan 2021 168 266 Peng 2010 126 502 Ma 2022 11 72 88 Construction 177 Construction 178 Construction 1					-		
Li 2019 116 236 Li 2022 88 895 Li 2022 88 895 Li 2022 88 112 Li 2021 103 565 Li 2022 58 112 Li 2021 88 30 106 Li 2022 2434 6413 Li 2021 88 30 106 Li 2022 953 4819 Li 2015 51 115 Ma 2022 953 4819 Ma 2022 953 4819 Ma 2022 953 4819 Li 2015 51 115 Peng 2010 126 502 Li 2015 194 256 Peng 2010 126 502 Li 2015 194 256 Peng 2010 126 502 Li 2015 194 472 Li 2015 194 472 Li 31 63 Li 2015 194 472 Li 31 63 Li 2022 33 60 Li 2015 194 472 Song 2014 83 134 Li 2015 194 472 Song 2014 83 134 Li 2016 251 Su 2009 42 200 Li 2015 Su 209 Li 2015 194 472 Song 2014 83 134 Li 2022 99 Li 2015 194 472 Song 2014 83 134 Li 2022 99 Li 2015 194 472 Song 2014 83 134 Li 2022 99 Li 2015 194 472 Li 2015 194 472 Song 2014 83 134 Li 2022 99 Li 2015 194 472 Song 2014 177 97 Li 2015 40 104 Li 2015 194 472 Song 2014 183 134 Li 2022 193 465 Su 2009 42 200 Li 2015 194 472 Li 2015 40 104 Li 2015 194 472 Li 2016 233 1408 Li 2022 194 483 Su 2009 44 200 Li 2016 233 1408 Li 2022 194 485 Su 2009 42 200 Li 2016 233 1408 Li 2017 71 10440, 0549 Li 2018 114 177 Li 2018 69 Li 2018 114 177 Li 2018 60 Li 2018 114 177 Li 2018 105 118 Li 2022 106 Li 2018 105 118 Li 2022 106 Li 2018 107 Li 2018 106							
Li 2022 88 895 0.051 0.055 0.0							
Liang 2021 103 565 Lin 2015 199 346 Lin 2012 68 112 Lin 2013 88 234 Liu 2018 30 106 Lin 2022 243 6413 Liu 2021 68 326 Liu 2021 69 161 Liu 2022 975 4819 Liu 2021 79 599 Liu 2022 975 4819 Liu 2015 61 115 Liu 2022 975 98 Liu 2015 61 115 Liu 2022 975 99 Liu 2022 97 Liu 202 Liu 2							
Lin 2015 199 346 - 0.546 [0.422: 0.60] Lin 2022 68 112 - 0.576 [0.314.0.442] Liu 2018 30 106 - 0.287 Liu 2018 30 106 - 0.287 Liu 2014 4 41 157 - 0.281 [0.194.0.337 Liu 2015 68 326 - 0.297 Ma 2020 93 162 - 0.573 [0.494.0.637 Ma 2021 99 161 - 0.553 [0.473.0.631 Ma 2022 97 509 - 0.191 [0.157.0.227 Ma 2021 198 161 - 0.553 [0.473.0.631 Ma 2022 97 509 - 0.191 [0.157.0.227 Ma 2021 168 286 - 0.557 [0.282.0.469 Peng 2010 126 502 - 0.557 [0.282.0.469 Oli 2022 31 63 - 0.492 [0.364.0.621 Oli 205 22 5 Sui 2000 42 200 - 0.113 - 0.451 [0.452 [0.455] Sui 200 42 200 - 0.113 - 0.451 [0.452 [0.455] Sui 200 42 200 - 0.113 - 0.451 [0.452 [0.455] Sui 200 42 200 - 0.113 - 0.451 [0.452 [0.455] Sui 200 42 200 - 0.113 - 0.451 [0.452 [0.455] Sui 200 42 200 - 0.41 [0.155 [0.274] Sui 2021 17 97 - 0.41 [0.452 [0.455] Sui 200 140 197 - 0.41 [0.452 [0.455] Sui 200 140 197 - 0.41 [0.440.0.544] Xu 2018 09 144 [0.460.0.448] Xu 2018 09 144 [0.460.0.448] Xu 2018 09 144 [0.460.0.448] Xu 2018 10.411 [0.440.0.544] Xu 2018 10.411 [0.440.0.544] Xu 2018 10.411 [0.440.0.544] Xu 2018 10.511 [0.450.0.774 Xu 2020 141 [0.518 [0.244] Zhang 2021 154 [0.518, p.=0] Findem effects model 6523 Pindem effects model 6523 Pin					-		
Lin 2022 66 112 Liu 2021 88 234 Liu 2018 30 106 Liu 2022 243 6413 Liu 2022 243 6413 Liu 2020 93 162 Ma 2020 93 162 Ma 2020 93 162 Ma 2022 953 4819 Ma 2021 166 286 Peng 2010 126 502 Peng 2010 126 502 Peng 2010 126 502 Peng 2010 126 502 Ma 2022 31 63 Cu 2022 31 63 Cu 2022 31 63 Cu 2022 61 178 Sin 2021 172 9 Ma 2021 9 Sin 2020 60 113 Sin 2021 172 199 Wi 2021 172 199 Wi 2021 172 199 Wi 2021 172 199 Wi 2021 174 0460 1053 Sin 2020 14 83 134 Sin 2021 177 97 Wi 2016 223 31 408 Wi 2016 223 31 408 Wi 2016 233 1408 Wi 2018 114 177 Sin 2021 179 9 Wi 2021 170 0 Wi 2018 164 0 Wi 2018 0 Wi 2020 166 026 0 Wi 2018 164 0 Wi 2020 166 026 0 Wi 2018 164 0 Wi 2018 0 Wi 201							
Liu 2016 30 106 0283 [2020 37] Liu 2022 2434 6413 - 0380 [3680 339] Liu 2015 668 326 - 0571 [0440 0651] Ma 2020 93 162 - 0574 [0449 0651] Ma 2022 953 4619 - 0574 [0449 0651] Ma 2022 953 4619 - 0578 [0470 0571 0571 0571 Ma 2022 97 509 - 0198 [0177 0227] Ma 2015 168 226 - 0577 [0520 0570 0571 0571 0571 0571 Ma 2021 168 226 - 0578 [0520 0570 0570 0572 0572 0572 0572 0572							
Liu 2014 41 157 - 0.261 [0.194.0.337] Liu 2022 2434 6413 - 0.209 [0.166.0.257] Ma 2020 93 162 - 0.776 [0.473.0.631] Ma 2021 89 161 - 0.653 [0.473.0.631] Ma 2022 953 4619 - 0.453 [0.473.0.631] Ma 2022 97 509 - 0.198 [0.167.0.259] Pan 2021 168 286 - 0.567 [0.520.0.45] Pan 2021 168 286 - 0.567 [0.520.0.45] Pan 2021 168 286 - 0.568 [0.271,0.271] Gi 2015 194 4258 - 0.576 [0.522,0.0.45] Pan 2022 31 63 - 0.449 [0.79] Gi 2015 194 4258 - 0.578 [0.523,0.445] Gi 2022 31 63 - 0.449 [0.79] Gi 2022 31 63 - 0.453 [0.449,0.79] Gi 2022 31 63 - 0.453 [0.449,0.79] Gi 2022 31 63 - 0.453 [0.449,0.79] Gi 2022 31 63 - 0.583 [0.449,0.79] Gi 2022 31 63 - 0.583 [0.449,0.79] Gi 2022 60 113 - 0.459 [0.552,0.702] Song 2020 60 113 - 0.531 [0.453,0.625] Si 2009 42 200 - 0.210 [0.156,0.273] Si 2021 72 189 - 0.210 [0.156,0.273] Si 2021 72 189 - 0.471 [0.460,0.622] Song 2020 60 113 - 0.531 [0.433,0.625] Si 2009 42 200 - 0.210 [0.156,0.273] Si 2021 72 189 - 0.576 [0.462,0.714] Xi 2021 17 97 - 0.175 [0.166,0.264] Vianer 2015 40 104 - 0.464 [0.560,0.714] Xi 2020 140 197 - 0.576 [0.432,0.707] Xi 2018 114 177 - 0.624 [0.536,0.707] Xi 2018 114 177 - 0.644 [0.560,0.714] Xi 2020 64 100 - 0.640 [0.530,0.707] Yang 2018 105 198 - 0.576 [0.332,0.427] Yang 2018 104 - 0.640 [0.530,0.707] Yang 2018 105 198 - 0.576 [0.330,0.707] Yang 2021 114 639 - 0.576 [0.330,0.777] Yang 2022 424 664 - 0.669 [0.444,0.564] Yang 2021 114 639 - 0.566 [0.446,0.166] Yang 2022 60 572 - 0.786,0.703 [0.330,0.777] Yang 2021 114 639 - 0.576 [0.330,0.777] Yang 2022 104 97 417 - 0.566 [0.466,0.628] Zhang 2021 114 639 - 0.576 [0.330,0.777] Yang 2021 114 639 - 0.576 [0.330,0.777] Yang 2021 114 639 - 0.576 [0.330,0.727] Zhang 2021 64 139 - 0.576 [0.330,0.777] Zhang 2021 64 139 - 0.576 [0.330,0.777] Zhang 2021 64 139 - 0.576 [0.337,0.427] Zhang 2021 114 639 - 0.576 [0.337,0.427] Zhang 2021 114 639 - 0.576 [0.337,0.427] Zhang 2021 114 639 - 0.576 [0.342,0.422] Zhang 2021 114 639 - 0.576 [0.342,0.422] Zhang 2021 114 639 - 0.576 [0.376,0.71]		Liu 2021	88	234		0.376	[0.314; 0.442]
Luo 2022 2434 6413 0.380 [0.386 [0.392] Luo 2015 68 326 - 0.574 [0.494 0.651] Ma 2021 89 161 - 0.553 [0.473 0.631] Ma 2022 953 4819 0.189 [0.167 0.229] Ma 2022 97 509 - 0.191 [0.157 0.229] Ma 2015 51 115 - 0.443 [0.351 0.539] Pan 2021 168 286 - 0.587 [0.528 0.464] Peng 2010 126 502 - 0.587 [0.528 0.464] Olay 2022 33 60 - 0.583 [0.494 0.769] Olay 2022 31 63 - 0.442 [0.364 0.627] Song 2014 83 134 - 0.649 [0.563 0.473 0.531] Sun 2021 172 189 - 0.547 [0.466 0.622] Song 2014 83 134 - 0.649 [0.562 0.722] Song 2014 83 134 - 0.649 [0.527] Sun 2021 172 189 - 0.531 [0.445 0.635] Su 2009 42 200 0.531 [0.445 0.635] Su 2009 42 200 0.531 [0.445 0.635] Su 2009 42 200 0.176 [0.327] Sun 2021 172 189 - 0.176 [0.166 0.246] Wu 2016 233 1408 - 0.166 [0.146 0.186] Wumaer 2015 40 104 - 0.386 [0.247] Sun 2021 179 97 - 0.175 [0.166 0.248] Su 2020 64 100 0.637 [0.563 0.734] Xu 2018 69 164 - 0.464 [0.563, 0.734] Xu 2018 69 164 - 0.464 [0.563, 0.734] Xu 2018 69 164 - 0.464 [0.563, 0.737] Xu 2018 69 164 - 0.464 [0.6460 0.648] Yang 2022 244 664 - 0.637 [0.563, 0.737] Yang 2022 244 664 - 0.637 [0.563, 0.737] Yang 2022 244 664 - 0.638 [0.217] 0.165 [0.248] Yang 2018 105 198 0.539 [0.648 0.0469] Yang 2012 1139 2182 - 0.638 [0.310, 0.246] Yang 2022 424 664 0.637 [0.563, 0.737] Yang 2022 424 664 0.637 [0.563, 0.737] Yang 2022 424 664 0.638 [0.310, 0.246] Yang 2018 105 198 0.538 [0.496, 0.489] Yang 2018 105 198 0.538 [0.496, 0.489] Yang 2018 105 198 0.538 [0.496, 0.489] Yang 2021 114 639 0.548 [0.466, 0.489] Yang 2022 111 108 190 0.548 [0.466, 0.588] Zhang 2016 197 502 0.337 [0.3		Liu 2018	30	106		0.283	[0.200; 0.379]
Luc 2015 68 326 + 0209 [0.166; 0.257] Ma 2020 93 162 - 0,553 [0.473; 0.631] Ma 2022 953 4819 - 0,198 [0.187; 0.229] Ma 2022 953 4819 - 0,198 [0.187; 0.229] Ma 2021 168 286 - 0,251 [0.528; 0.845] Pan 2021 168 286 - 0,251 [0.528; 0.845] Pan 2021 168 286 - 0,251 [0.528; 0.845] Pan 2022 31 63 - 0,482 [0.344; 0.709] Gi 2015 194 258 - 0,583 [0.446; 0.749] Gi 2012 194 172 - 0,583 [0.446; 0.749] Gi 2022 61 178 - 0,484 [0.358] [0.446; 0.749] Gi 2022 61 178 - 0,484 [0.358] [0.446; 0.749] Gi 2022 61 178 - 0,583 [0.446; 0.729] Song 202 60 113 - 0,583 [0.446; 0.729] Sin 2021 72 189 - 0,581 [0.311] (0.454) Wei 2021 17 97 - 0,574 [0.466; 0.422] Sin 2021 72 189 - 0,581 [0.311] (0.454) Wi 2016 233 1408 - 0,175 [0.166; 0.246] Wuxaer 2015 40 104 - 0,166 [0.146(0.186] Wuxaer 2015 40 104 - 0,164 [0.536; 0.774] Xia 202 92 29 209 - 0,474 [0.464, 0.564] Xia 202 140 197 - 0,574 [0.466; 0.162] Xia 2018 69 164 - 0,464 [0.566; 0.714] Xia 202 16 114 177 - 0,644 [0.566; 0.714] Xia 2018 69 164 - 0,640 [0.580; 0.734] Xia 2018 104 - 0,640 [0.580; 0.734] Xia 2018 104 - 0,640 [0.580; 0.734] Xia 2018 104 - 0,640 [0.580; 0.74] Xia 202 16 114 177 - 0,644 [0.466; 0.682] Zhang 202 2,256 572 - 0,7865 [0.603] [0.6010,675] Ye 202 38 02 21 3 - 0,776 [0.332; 0.427] Zhang 202 52 240 - 0,640 [0.274; 0.412] Zhang 202 52 240 - 0,640 [0.274; 0.412] Zhang 202 52 240 - 0,640 [0.274; 0.412] Zhang 202 51 11 108 190 - 0,640 [0.274; 0.412] Zhang 202 51 11 108 190 - 0,640 [0.274; 0.412] Zhang 202 51 114 539 - 0,776 [0.332; 0.427] Zhang 202 51 14 53 171 - 0,566 [0.446; 0.466] Zhang 202 61 137 - 0,776 [0.680; 0.244] Zhang 202 61 137 - 0,776 [0.680; 0.244] Zhang 202 61 137 - 0,776 [0.680; 0.244] Zhang 202 61 137 - 0,776 [0.332; 0.427] Zhang 202 61 137 - 0,776 [0.332; 0.427]		Liu2014	41			0.261	[0.194; 0.337]
Ma 2020 93 162					ф.		
Ma 2021 89 161					<u>₹</u>		
Ma 2022 953 4819 0.198 0.177, 0.227 Ma 2015 51 115 0.431 10.377, 0.227 Ma 2015 51 116 0.265 0.657 10.522 0.657 0.525 0.646 Qual 2022 31 63 0.722 10.682 0.251 0.221 0.025 0.657 0.522 0.665 0.803 0.449 0.769 0.722 10.646 0.683 0.449 0.769 0.723 0.477 0.469 0.622 0.651 10.449 0.762 0.649 0.633 0.637 0.449 0.762 0.762 0.649 0.532 0.762 0.762 0.765 0.649 0.752 0.762 0.649 0.532 0.762 0.765 0.649 0.532 0.762 0.765 0.765 0.765 0.752 0.762 0.761 0.765 0.765 0.765 0.765 0.765 0.765 0.765 0.765 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761 0.761							
Ma 2022 97 509 9 0.191 [0.157.0227 Ma 2015 51 115 0.435 (0.538) Peng 2010 126 502 0.251 [0.214:0.291 Q12015 144 258 0.469 Qu 2022 31 63 0.492 (0.268) 0.430 (0.268) Qu 2022 61 178 0.492 (0.268) 0.430 (0.268) 0.449 (0.709 Qu 2022 61 178 0.492 (0.268) 0.430 (0.268) 0.449 (0.709 Qu 2022 61 178 0.492 (0.268) 0.430 (0.268) 0.449 (0.262) Song 2014 83 134 0.492 (0.208 (0.268) 0.492 (0.268) 0.430 (0.273) Sun 2021 72 189 0.491 (0.156 (0.273) Sun 2021 72 189 0.491 (0.256) 0.231 (0.468 (0.268) 0.231 (0.268 (0.274) 0.238 (0.231 (0.268 (0.231 (0.238 (0.231 (0.268 (0.231 (0.							
Ma 2015 5 1 115 - 0.443 [0.351] 0.539 Pan 2021 166 286 - 0.551 [0.214] 0.291 Q1 2015 194 256 - 0.551 [0.214] 0.291 Q1 2022 35 60 - 0.553 [0.469] 0.709 Qu 2022 31 63 - 0.492 [0.364] 0.621 Quan 2022 61 178 - 0.492 [0.364] 0.621 Song 2014 83 134 - 0.619 [0.532] 0.723 Song 2020 60 113 - 0.651 [0.453] 0.625 Su 2009 42 200 - 0.511 [0.453] 0.625 Su 2011 72 189 - 0.511 [0.453] 0.625 Su 2020 160 113 - 0.619 [0.522] 0.723 Sun 2021 72 189 - 0.511 [0.453] 0.625 Su 2016 233 1408 - 0.615 [0.342] 0.715 [0.166] 0.266 Wumaer 2015 40 104 - 0.385 [0.291] 0.455 0.265 Su 2020 64 100 - 0.75 [0.166] 0.266 Wumaer 2015 40 104 - 0.485 0.291 Xu 2018 114 177 - 0.614 [0.563] 0.771 Xu 2018 169 164 - 0.640 [0.538] 0.734 Xu 2018 164 - 0.640 [0.563] 0.771 Yan 2022 256 572 - 0.448 [0.466] 0.639 Yang 2018 105 198 - 0.639 [0.601] 0.675 Ye 2023 80 213 - 0.639 [0.601] 0.675 Ye 2023 80 213 - 0.639 [0.601] 0.675 Ye 2023 80 213 - 0.639 [0.601] 0.675 Yang 2014 97 417 - 0.644 [0.568] 0.744 Xue 2019 116 182 - 0.639 [0.631] 0.745 Yang 2018 105 198 - 0.530 (0.571) Yang 2018 105 198 - 0.530 (0.571) Yang 2022 424 664 - 0.639 [0.601] 0.675 Ye 2023 80 213 - 0.530 (0.771) Yang 2024 64 640 - 0.538 (0.742] Yang 2018 105 198 - 0.530 (0.771) Yang 2022 424 664 - 0.639 [0.661] 0.675 Ye 2023 80 213 - 0.376 [0.332] 0.458 (0.611) Yang 2020 64 320 - 0.376 [0.332] 0.458 (0.611) Yang 2020 64 320 - 0.385 [0.291] 0.548 (0.406) Zhang 2020 62 240 - 0.558 (0.377) Zhang 2011 108 190 - 0.568 (0.370) Zhang 2021 62 110 - 0.568 (0.274] Zhang 2021 62 110 - 0.568 (0.248) Zhang 2021 64 68 260 - 0.576 Zhang 2021 62 110 - 0.568 (0.248) Zhang 2021 144 59 - 0.568 (0.274) Zhang 2021 62 110 - 0.568 (0.248) Zhang 2021 1405 5414 - 0.260 [0.248] 0.271 Zhang 2021 62 110 - 0.568 (0.248] Zhang 2021 1405 5414 - 0.260 [0.248] 0.271 Zhang 2021 62 110 - 0.568 (0.248] Zhang 2021 1405 5414 - 0.260 [0.248] 0.271 Zhang 2021 1405 5414 - 0.260 [0.							
Pan 2021 166 286					*		
Peng 2010 126 502							
Qi 2015 194 258 → 0.752 0.695 0.803 Qin 2022 35 60 0.895 0.449 0.772 0.449 0.773 Quan 2022 61 178 0.449 0.776 0.695 0.833 0.449 0.773 0.417 Shi 2021 94 172 → 0.511 0.433 0.273 0.417 Song 2020 60 113 → 0.511 0.453 0.623 Su 2009 42 200 → 0.311 0.455 0.626 Wei 2021 77 179 → 0.717 0.106 0.273 Su 2020 140 140 - 0.385 0.291 0.381 0.311 0.454 Vu2016 233 1408 0.440 0.440 0.440 0.440 0.440 0.440 0.440 0.440 0.440 0.440 0.508 0.741 Vu202 140 197 → 0.711 0.640 0.538 0.734 Vu2020 140 164 197					-		
Clin 2022 35 60 0.499, 0.709 Qua 2022 31 63 0.499, 0.709 Qua 2022 31 63 0.499, 0.709 Song 2014 83 134 0.849, 0.709 Song 2020 60 113 0.537 0.499, 0.709 Song 2020 60 113 0.531 0.435, 0.625 Su 2009 42 200 0.210 0.156, 0.273 Sun 2021 72 189 0.381 0.311, 0.454 Wei 2021 17 97 0.75 0.106, 0.266 Wu 2016 233 1408 0.465 0.146, 0.186 Wu 2016 233 1408 0.465 0.444, 0.509, 0.714 Xu 2020 140 197 0.474 0.404, 0.544 Xu 2020 140 197 0.474 0.404, 0.549, 0.714 Xu 2020 64 100							
Qu 2022 31 63							
Quan 2022 61 178 0.343 0.273: 0.417 Shi 2021 94 172 0.619 0.532: 0.702 Song 2020 60 113 0.619 0.532: 0.702 Song 2020 60 113 0.619 0.532: 0.702 Sun 2021 72 189 0.715 0.165: 0.273 Sun 2021 17 97 0.175 0.165: 0.273 Wei 2021 17 97 0.175 0.165: 0.273 Wimaer 2015 40 104 0.385 0.291: 0.485 Xu 2020 140 197 0.385 0.291: 0.485 Xu 2020 140 197 0.474 0.404: 0.544 Xu 2020 64 100 0.644 0.669: 0.714 Xue 2018 114 177 0.673 0.663: 0.707 Yan 2022 256 572 0.474 0.404: 0.549 Yang 2018 105 198 0.331 0.016: 0.749 Yang 2018 105 198 0.366 0.037: 0.426; 0.075 Yang 2011 108 199 0							
Shi 2021 94 172							
Song 2020 60 113		Shi 2021	94	172			
Su 2009 42 200		Song 2014	83	134		0.619	[0.532; 0.702]
Sun 2021 72 189							
Wei 2021 17 97		Su 2009				0.210	[0.156; 0.273]
Wu 2016 233 1408 0.165 $[0.146; 0.186]$ Wumaer 2015 40 104 0.385 $[0.291; 0.485]$ Xi 2022 99 209 0.474 $[0.404; 0.544]$ Xu 2018 69 164 0.462; 0.773] Xu 2018 619 164 0.669; 0.714] Xue 2010 64 100 0.663 $[0.533; 0.734]$ Xue 2019 116 182 0.640 $[0.533; 0.734]$ Yang 2022 256 572 0.448 $[0.406; 0.489]$ Yang 2018 105 198 0.633 $[0.601; 0.675]$ Ye 2023 80 213 0.637 $[0.346; 0.430]$ Yang 2014 97 417 0.376 $[0.310; 0.276]$ Zhang 2008 66 194 0.4064 $[0.566; 0.436]$ Zhang 2011 108 190							
Wumaer 2015 40 104							
Xi 2022 99 209 0,474 0,404: 0.544 Xu 2020 140 197 0,711 10,642: 0.773 Xu 2018 114 177 0,644 0,569: 0.714 Xue 2018 114 177 0,644 0,569: 0.774 Xue 2019 116 182 0,644 0,563: 0.707 Yan 2022 256 572 0,448 0,6637 0,563: 0.707 Yang 2018 105 198 0,448 0,406: 0,489 0,448 0,406: 0,489 Yang 2022 424 664 0,533 0,010: 0,675 0,376 0,376 0,310: 0,444 Yuan 2021 139 2182 0,064 0,054: 0,075 0,345: 0,430 Zhang 2008 2013 525 0,337 0,337 0,337 0,337 0,337 0,337 0,345: 0,430 0,274: 0,412 Zhang 2008 203 525 0,349 0,344: 0,359: 0,429 0,274: 0,412 166: 0,274 0,349: 0,359: 0,429 2,171 166: 0,274 0,349: 0,359: 0,429 2,171 166: 0,274 0,349: 0,359: 0,429 2,171 166: 0,274: 0,							
Xu 2020 140 197							
Xu 2018 69 164							
Xue 2018 114 177							
Xue 2020 64 100							
Xue 2019 116 182							
Yan 2022256572 $+$ 0.448(0.406: 0.489)Yang 20181051980.530(0.458: 0.601)Yang 20224246640.639(0.601: 0.675)Zhang 201413921820.640.0233Zhang 20082035250.387(0.345: 0.430)Zhang 2008661940.340(0.274: 0.412)Zhang 202052240-0.568Zhang 20211146390.176: 0.274: 0.412)Zhang 202052240-0.176: 0.274: 0.412)Zhang 2021114639-0.394: 0.399: 0.276)Zhang 2021114639-0.178: 0.149: 0.210)Zhao 202064320-0.200Zhao 2014138171-0.807: 0.740: 0.863)Zhao 2014138171-0.807: 0.776: 0.666: 0.644)Zhao 2014138171-0.877: 0.227: 0.427!Zhao 20141381010.376: [0.332; 0.422]Zhao 201414055414-0.376: [0.332; 0.422]Zhao 201214055414-0.376: [0.332; 0.422]Random effects model53623-0.376: [0.332; 0.422]Heterogeneity: l^2 = 98%, s^2 = 0.7585, ρ = 0-0.376: [0.332; 0.422]							
Yang 2018105198 $-$ 0.5300.458:0.601Yang 2022424664 $-$ 0.6390.601:0.675Ye 202380213 $-$ 0.3760.301:0.444Yuan 20211392182 $-$ 0.6340.054:0.075Zhang 201497417 $-$ 0.2330.193:0.276Zhang 200866194 $-$ 0.346:0.3370.345:0.344:0.35:0.345:0.345:0.345:0.345:0.345:0.345:0.345:0.345:0.344:0.355:0.429:Zhang 202152240 $-$ 0.217:1.066:0.274:0.176:0.248:0.217:0.166:0.274:0.392:0.327:0.227:0.327:0.226:0.265:0.327:0.427:0.327:0.237:0.227:0.327:0.227:0.327:0.237:0.237:0.237:0.237:0.237:0.237:0.237:0.237:							
Yang 2022424664 $=$ 0.6390.601: 0.675Ye 202380213 $=$ 0.3760.310: 0.441Yuan 20211392182 $=$ 0.0640.064Zhang 201497417 $=$ 0.2330.193: 0.276Zhang 200866194 $=$ 0.3400.274: 0.412Zhang 2011108190 $=$ 0.5680.495: 0.640Zhang 202052240 $=$ 0.21710.166: 0.274Zhang 2021114639 $=$ 0.1780.149: 0.210Zhang 202064320 $=$ 0.200[0.158: 0.248]Zhao 2016197502 $=$ 0.392[0.349: 0.437]Zhao 2014138171 $=$ 0.807[0.740: 0.863]Zhau 20115976 $=$ 0.262[0.209: 0.319]Zhao 2014138101 $=$ 0.376[0.332; 0.422]Zhau 20115976 $=$ 0.376[0.332; 0.422]Zhau 201233101 $=$ 0.376[0.332; 0.422]Zhau 201314055414 $=$ 0.376[0.332; 0.422]Random effects model53623 $=$ 0.376[0.332; 0.422]Heterogeneity: l^2 = 98%, s^2 = 0.7585, p = 0 $=$ 0.376[0.332; 0.422]							
Ye 2023 80 213 0.376 0.310 0.444 Yuan 2021 139 2182 0.064 (0.054) 0.075 Zhang 2014 97 417 0.387 (0.345) 0.430 Zhang 2008 203 525 0.387 (0.345) 0.430 Zhang 2008 66 194 0.340 (0.274) 0.412 Zhang 2020 52 240 0.568 (0.495) 0.640] Zhang 2020 52 240 0.217 (166) 0.274 Zhang 2021 114 639 0.178 (0.149) 0.210] Zhao 2020 64 320 0.392 (0.392) 0.429] Zhao 2016 197 502 0.392 (0.392) 0.437] Zhao 2014 138 171 0.807 (0.740) 0.863] 0.866 0.864] Zhou 2018 68 260 0.327 0.227] 0.327 0.227] 0.327 0.227] 0.227 0.327 0.227] 0.327 0.227] 0.327 0.227 0.327							
Yuan 2021 139 2182 0.064 0.054 0.075 Zhang 2014 97 417 0.233 0.193: 0.276 Zhang 2008 203 525 0.347 0.345: 0.430 Zhang 2011 108 190 0.464 0.0243: 0.640 Zhang 2012 52 240 0.568 0.495: 0.640 Zhang 2020 52 240 0.394 0.359: 0.429 Zhang 2021 114 639 0.178 0.186: 0.274 Zhao 2020 64 320 0.178: 0.149: 0.210 0.158: 0.248 Zhao 2016 197 502 0.392 0.392: 0.349: 0.437 Zhao 2016 197 502 0.392 0.392: 0.349: 0.437 Zhao 2016 197 502 0.392 0.392: 0.349: 0.437 Zhao 2014 138 171 0.807 0.740: 0.863 Zhou 2018 68 260 0.262 0.209: 0.319 Zhou 2011 59 76 0.327: 0.427 0.227: 0.422 Zhou 2021 1405 5414 0.327: 0.427 0.260 0.248: 0.					- <u></u>		
Zhang 2014 97 417					•		
Zhang 2008 203 525 - 0.387 $[0.345; 0.430]$ Zhang 2008 66 194 0.340 $[0.274; 0.412]$ Zhang 2011 108 190 - 0.568 $[0.495; 0.640]$ Zhang 2020 52 240 - 0.217 $[0.166; 0.274]$ Zhang 2020 52 240 - 0.349 $[0.359; 0.429]$ Zhang 2021 114 639 - 0.200 $[0.156; 0.248]$ Zhao 2020 64 320 - 0.200 $[0.156; 0.248]$ Zhao 2016 197 502 0.392 $[0.349; 0.437]$ Zhao 2014 138 171 - 0.807 $[0.740; 0.863]$ Zhou 2018 68 260 - 0.564 $[0.466; 0.658]$ Zhou 2011 59 76 - 0.327 $[0.237; 0.427]$ Zhou 2011 59 76 - 0.327 $[0.237; 0.427]$ Zhou 2011 59 76 - 0.327 $[0.237; 0.427]$ Zhou 2021 1405 5414 0.260							
Zhang 2008 66 194 0.274; 0.412] Zhang 2011 108 190 0.568 [0.495; 0.640] Zhang 2020 52 240 0.217 [166; 0.274] Zhang 2022 303 770 0.394 [0.359; 0.429] Zhang 2020 64 320 0.178 [0.186; 0.274] Zhao 2020 64 320 0.178 [0.186; 0.274] Zhao 2016 197 502 0.392 [0.349; 0.437] Zhao 2016 197 502 0.392 [0.349; 0.437] Zhao 2014 138 171 0.807 [0.740; 0.666] Zheng 2021 62 110 0.807 [0.740; 0.666] Zhou 2018 68 260 0.262 [0.299; 0.319] Zhou 2011 59 76 0.327 0.237; 0.427] Zou 2021 1405 5414 0.327 0.260 [0.248; 0.271] Random effects model 53623 0.376 [0.332; 0.422] 0.376 [0.332; 0.422]							
Zhang 2011 108 190 0.568 [0.495; 0.640] Zhang 2020 52 240 0.217 [0.166; 0.274] Zhang 2021 303 770 0.394 [0.359; 0.429] Zhang 2021 114 639 0.394 [0.359; 0.429] Zhao 2020 64 320 0.392 [0.349; 0.447] Zhao 2016 197 502 0.392 [0.349; 0.437] Zhao 2014 138 171 0.564 [0.466; 0.658] Zhou 2018 68 260 0.564 [0.466; 0.658] Zhou 2011 59 76 0.776 [0.666; 0.864] Zhou 2022 33 101 0.327 [0.237; 0.427] Zou 2021 1405 5414 0.376 [0.332; 0.422] Heterogeneity: l^2 = 98%, r^2 = 0.7585, ρ = 0 0.376 [0.332; 0.422]					- 100 ²		
Zhang 2020 52 240 - 0.217 [0.166; 0.274] Zhang 2022 303 770 - 0.394 [0.359, 0.429] Zhang 2021 114 639 - 0.178 [0.149; 0.210] Zhao 2020 64 320 - 0.392 [0.349; 0.437] Zhao 2016 197 502 - 0.392 [0.349; 0.437] Zhao 2014 138 171 - 0.807 [0.740; 0.863] Zhou 2018 68 260 - 0.554 [0.466; 0.658] Zhou 2011 59 76 - 0.776 [0.666; 0.237; 0.427] Zhou 2011 59 76 - 0.327 [0.237; 0.427] Zhou 2011 59 76 - 0.327 [0.237; 0.427] Zou 2021 1405 5414 - 0.327 [0.237; 0.427] Badom effects model 53623 - 0.376 [0.332; 0.422] Heterogeneity: $l^2 = 98\%, t^2 = 0.7585, \rho = 0$ - 0.376 [0.332; 0.422]							
Zhang 2022 303 770 - 0.394 [0.359: 0.429] Zhang 2021 114 639 - 0.200 [0.149: 0.210] Zhao 2020 64 320 - 0.392 [0.349: 0.437] Zhao 2016 197 502 - 0.392 [0.349: 0.437] Zhao 2014 138 171 - 0.807 [0.740: 0.863] Zheng 2021 62 110 - 0.564 (0.466: 0.658) Zhou 2018 68 260 - 0.262 [0.209: 0.319] Zhou 2011 59 76 - 0.327 [0.237: 0.427] Zou 2021 1405 5414 - 0.260 [0.248: 0.271] Random effects model 53623 - 0.376 [0.332; 0.422] Heterogeneity: $l^2 = 98\%$, $s^2 = 0.7585$, $p = 0$ - 0.376 [0.332; 0.422]		Zhang 2020		240	- <u></u>	0.217	[0.166; 0.274]
Zhao 2020 64 320 0.200 $[0.158; 0.248]$ Zhao 2016 197 502 0.392 $[0.349; 0.437]$ Zhao 2014 138 171 0.807 $[0.740; 0.863]$ Zhou 2018 68 260 0.262 $[0.209; 0.319]$ Zhou 2011 59 76 0.776 $[0.666; 0.864]$ Zhou 2022 33 101 0.327 $[0.237; 0.427]$ Zou 2021 1405 5414 0.260 $[0.332; 0.422]$ Heterogeneity: $l^2 = 98\%$, $t^2 = 0.7585$, $p = 0$ 0.376 $[0.332; 0.422]$		Zhang 2022				0.394	[0.359; 0.429]
Zhao 2016 197 502 0.392 0.362 0.564 0.666 0.668 0.262 0.209 0.319 0.262 0.209 0.319 0.327 0.227 0.427 0.327 0.227 0.327 0.227 0.237 0.227 0.237 0.227 0.237 0.227 0.277 <t< td=""><td></td><td></td><td></td><td></td><td>H</td><td></td><td></td></t<>					H		
Zhao 2014 138 171							
Zheng 2021 62 110 0.564 [0.466; 0.658] Zhou 2018 68 260 0.262 [0.209; 0.319] Zhou 2011 59 76 0.776 [0.66; 0.664] Zhuo 2022 33 101 0.327 [0.237; 0.427] Zou 2021 1405 5414 0.260 [0.322; 0.422] Random effects model 53623 \bigcirc 0.376 [0.332; 0.422] Heterogeneity: $l^2 = 98\%$, $t^2 = 0.7585$, $\rho = 0$ \bigcirc \bigcirc \bigcirc \bigcirc							
Zhou 2018 68 260 0.262 $[0, 209; 0.319]$ Zhou 2011 59 76 0.776 $[0.666; 0.864]$ Zhuo 2022 33 101 0.327 $[0.237; 0.427]$ Zou 2021 1405 5414 0.260 $[0.248; 0.271]$ Random effects model 53623 \bigcirc 0.376 $[0.332; 0.422]$ Heterogeneity: $l^2 = 98\%$, $t^2 = 0.7585$, $\rho = 0$ \bigcirc \bigcirc \bigcirc \bigcirc							
Zhou 2011 59 76 0.776 0.666; 0.864] Zhuo 2022 33 101 0.327 0.237; 0.427] Zou 2021 1405 5414 0.260 [0.248; 0.271] Random effects model 53623 \bigcirc 0.376 [0.332; 0.422] Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $\rho = 0$ \bigcirc \bigcirc \bigcirc \bigcirc							
Zhuo 2022 33 101 0.327 $[0.237; 0.427]$ Zou 2021 1405 5414 0.260 $[0.248; 0.271]$ Random effects model 53623 \bigcirc 0.376 $[0.332; 0.422]$ Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $\rho = 0$ \bigcirc \bigcirc \bigcirc \bigcirc					- <u>-</u>		
Zou 2021 1405 5414 0.260 $[0.248; 0.271]$ Random effects model Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $\rho = 0$ 0.376 $[0.332; 0.422]$							
Random effects model 53623 \diamond 0.376 [0.332; 0.422] Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $\rho = 0$ \bullet \bullet \bullet							
Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $p = 0$		20U 2021	1405	5414		0.260	[0.248; 0.271]
Heterogeneity: $l^2 = 98\%$, $\tau^2 = 0.7585$, $p = 0$		Pandom offecte model		53633	1	0.370	10 332. 0 4223
			0 7595			0.376	[0.332, 0.422]
0.2 0.4 0.0 0.0	1	neterogeneity. / = 98%, t"=	0.7585	p = 0	02 04 06 08		
					0.2 0.4 0.0 0.8		

FIGURE 2

The forest plot of the overall pooled prevalence of cognitive impairment in Chinese patients with hypertension.

TABLE 1 Subgroup analysis and risk factors for cognitive impairment in hypertension.

Risk	Number of	Number of	Pooled	Heterogeneity		OR/r (95%CI)	Heterogeneity	
factors	studies (n)	subjects (n)	prevalence (95%CI)	l ²	Р		1 ²	Р
Gender								
Male subjects	49	13,695	32.1% (31.6-43.0%)	97%	< 0.01	1.0	/	/
Female subjects	48	15,974	40.3% (34.9-45.9%)	97%	< 0.01	1.15 (1.01–1.32)	91%	< 0.01
Body weight statu	15							
BMI≤24	5	4,532	33.4% (24.3-43.8%)	78%	< 0.01	1.0	/	/
BMI>24	5	2,859	46.0% (36.5-55.7%)	96%	< 0.01	1.76 (1.04-3.00)	91%	< 0.01
Educational level			· · · · · ·					
Middle school and above	16	5,829	26.9% (17.6-38.8%)	96%	<0.01	1.0	/	/
Primary school and below	15	4,258	36.5% (26.1-48.2%)	97%	<0.01	2.01 (1.10-3.67)	98%	< 0.01
Family status		1	11			1		
Married	9	10,643	21.4% (13.4-32.2%)	99%	< 0.01	1.0	1	/
Single	9	2,822	31.7% (21.2-44.6%)	97%	< 0.01	1.63 (1.32-2.02)	61%	< 0.01
Duration of hype	rtension	1			1	1		
<5 years	2	2,363	24.2% (16.5-34.0%)	91%	< 0.01	1.0	1	/
5~10 years	2	472	30.8% (12.1-58.9%)	97%	<0.01	1.29 (0.49-3.41)	88%	< 0.01
>10 years	2	2,295	33.5% (17.1–55.1%)	97%	< 0.01	1.08 (0.93-1.25)	0%	0.33
Complication wit	th diabetes							
Without	18	7,915	39.9% (31.7-48.7%)	95%	< 0.01	1.0	/	/
diabetes								
With diabetes	18	1724	47.8% (38.3-57.4%)	90%	< 0.01	1.44 (1.14-1.80)	64%	< 0.01
Complication wit	th CHD	1	11		1	1	1	
Without CHD	14	7,459	35.5% (24.9-47.6%)	94%	< 0.01	1.0	/	/
With CHD	14	1,197	44.6% (32.9-56.9%)	96%	<0.01	1.49 (1.12, 1.97)	59%	< 0.01
Classification of l	hypertension	1	11		1	1		
I	10	1,105	28.5% (20.6-37.9%)	88%	< 0.01	1.0	/	/
II	12	1,467	40.1% (29.1-52.1%)	90%	<0.01	1.83 (1.29-2.60)	61%	< 0.01
III	12	913	55.5% (37.6–72%)	87%	<0.01	3.08 (1.82-5.22)	73%	< 0.01
Smoking habits			11					
Smokers	24	4,643	38.7% (31.8-46.2%)	96%	< 0.01	1.0	/	/
Non-smokers	24	2,932	37.3% (30.2-44.9%)	90%	<0.01	0.93 (0.76-1.15)	60%	< 0.01
Drinking habits						, ,		
No drinking habits	20	8,734	32.8% (26.0%-40.4)	96%	<0.01	1.0	/	/
Drinking habits	20	1859	33.5% (25.3-42.9%)	93%	<0.01	1.07 (0.85-1.35)	52%	< 0.01
Physical activity								
Regular	7	1777	45.1% (25.4–66.4%)	98%	<0.01	1.0	1	/
physical activity								
No regular physical activity	7	6,241	24.4% (9.5-49.9%)	98%	<0.01	0.40 (0.21–0.77)	92%	<0.01
Age	4	903	/	/	/	-0.34 (-0.45, -0.21)	75%	< 0.001
SBP	3	732	/	/	/	-0.25 (-0.42, -0.08)	82%	0.005
DBP	3	742	/	/	/	0.08 (-0.18-0.33)	91%	0.54
Нсу	4	691	/	/	/	-0.39 (-0.63, -0.09)	94%	0.01
hs-CRP	2	412	/	/	/	-0.04 (-0.13-0.06)	0%	0.47
IL-6	3	672	/	/	/	-0.26 (-0.48, -0.02)	87%	0.03

higher prevalence of cognitive impairment was observed in patients with CHD (44.6, 95% CI: 32.9–56.9%, $I^2 = 94\%$, p < 0.01) compared to those without CHD (35.5, 95% CI: 24.9–47.6%, $I^2 = 96\%$, p < 0.01; Supplementary Figure 10C). The OR in patients with CHD compared to those without CHD was 1.49 (95% CI: 1.12–1.97, $I^2 = 59\%$, p < 0.01; Supplementary Figure 10D).

3.5.7 Classification of hypertension

In total, 12 studies included 1,105, 1,467, and 913 patients with stage 1, stage 2, and stage 3 hypertension, respectively. The prevalence of cognitive impairment in patients with stage 3 hypertension (55.5, 95% CI: 37.6–72.0%, $I^2 = 87\%$, p < 0.01) was higher than that in patients with stage 2 hypertension (40.1, 95% CI: 29.1–52.1%, $I^2 = 90\%$, p < 0.01) and stage 1 hypertension (28.5, 95% CI: 20.6–37.9%, $I^2 = 88\%$, p < 0.01; Supplementary Figure 11A). There was a statistical difference among the three groups (stage 3 vs. stage 1, OR = 3.08, 95% CI: 1.82–5.22, $I^2 = 73\%$, p < 0.01; stage 2 vs. stage 1, OR = 1.83, 95% CI: 1.29–2.60, $I^2 = 61\%$, p < 0.01; Supplementary Figures 11B,C).

3.5.8 Smoking habits

A total of 24 studies evaluated the prevalence of cognitive impairment in 2,932 and 4,643 patients with hypertension with and without smoking habits, respectively. The prevalence of cognitive impairment was higher in patients with hypertension without smoking habits (38.7, 95% CI: 31.8–46.2%, $I^2 = 96\%$, p < 0.01) than in those with smoking habits (37.3, 95% CI: 30.2–44.9%, $I^2 = 90\%$, p < 0.01; Supplementary Figure 12A). The OR of patients with hypertension with smoking habits compared to those without smoking habits was 0.93 (95% CI: 0.76–1.15, $I^2 = 60\%$, p < 0.01; Supplementary Figure 12B).

3.5.9 Drinking habits

There were 20 studies with 1,859 and 8,734 patients with hypertension with and without drinking habits, respectively. The prevalence of cognitive impairment was 33.5% (95% CI: 25.3–42.9%, $I^2 = 93\%$, p < 0.01) in patients with hypertension with drinking habits and 32.8% (95% CI: 26.0–40.4%, $I^2 = 96\%$, p < 0.01) in those without drinking habits (Supplementary Figure 13A). No statistical difference was detected between the two groups (with drinking habits vs. without drinking habits, OR = 1.07, 95% CI: 0.85–1.35, $I^2 = 52\%$, p < 0.01; Supplementary Figure 13B).

3.5.10 Regular physical activity

Seven studies investigated the prevalence of cognitive impairment in 6,241 and 1,777 patients with hypertension who engaged in regular physical activity and those who did not. A higher prevalence was observed in patients without regular physical activity (45.1, 95% CI: 25.4–66.4%, $I^2 = 98\%$, p < 0.01; Supplementary Figure 14A) than in those with regular physical activity (24.4, 95% CI: 9.5–49.9%, $I^2 = 98\%$, p < 0.01). Compared with those without regular physical activity, the OR for those with regular physical activity was 0.40 (95% CI: 0.21– 0.77, $I^2 = 92\%$, p < 0.01; Supplementary Figure 14B).

3.5.11 Age

The pooled results of four studies indicated that age was negatively associated with cognitive function in patients with hypertension (r = -0.34, 95% CI: -0.45, -0.21, $I^2 = 75\%$, p < 0.001; Supplementary Figure 15).

3.5.12 SBP

The pooled results demonstrated that there was a negative correlation between SBP and cognitive function in patients with hypertension (r=-0.25, 95% CI: -0.42, -0.08, $I^2 = 82\%$, p = 0.005; Supplementary Figure 16).

3.5.13 DBP

No significant association was detected between DBP and cognitive function in patients with hypertension (r=0.08, 95% CI: -0.18-0.33, $I^2 = 91\%$, p = 0.54; Supplementary Figure 17).

3.5.14 Hcy

Hcy was adversely associated with cognitive function in patients with hypertension (r = -0.39, 95% CI: -0.63, -0.09, $I^2 = 94\%$, p = 0.01; Supplementary Figure 18).

3.5.15 hs-CRP

There was no correlation between hs-CRP and cognitive function in patients with hypertension (r = -0.04, 95% CI: -0.13-0.06, $I^2 = 0\%$, p = 0.47; Supplementary Figure 19).

3.5.16 Interleukin-6

IL-6 was inversely correlated with cognitive function in patients with hypertension (r = -0.26, 95% CI: -0.48, -0.02, $I^2 = 87\%$, p = 0.03; Supplementary Figure 20).

3.6 Sensitivity analysis

The pooled prevalence of cognitive impairment in patients with hypertension varied from 37.1 to 38.2% after omitting the studies one by one, which indicated good stability (Supplementary Figure 21).

3.7 Publication bias


The asymmetry funnel plot and the results of *Egger's* test (p=0.0029) indicated that publication bias existed in the prevalence of cognitive impairment in patients with hypertension. The trim and fill method was used and the results remained consistent with 22 additional virtual studies (Figure 3).

3.8 Meta-regression analysis

The results of univariate meta-regression showed that the study characteristics of recruitment source, study design, and cognitive impairment assessment tools could be potential sources of heterogeneity (Supplementary Table 6).

3.9 Certainty of evidence

The certainty of evidence was assessed for the prevalence of cognitive impairment in patients with hypertension. The certainty for the prevalence of cognitive impairment in Chinese patients with hypertension was upgraded from very low to low because of "a large sample size effect" (Supplementary Table 7).



4 Discussion

4.1 Cognitive impairment is prevalent in Chinese patients with hypertension

The present study included 82 studies involving 53,623 hypertensive patients, and the pooled prevalence of cognitive impairment (mild to severe) in Chinese patients with hypertension was 37.6%, indicating that cognitive impairment was prevalent. Inconsistently, according to the subgroup analysis of a recent metaanalysis (17), it was reported that the prevalence of MCI in Asian hypertensive patients was 26%, which was lower than the global prevalence of 30%. Such differences may be attributed to different study regions (China vs. Asia). Several epidemiological investigations have been conducted in Argentina (24), Spain (25) and Poland (26), reporting a prevalence of 22.1%, 15.7%, and 17.7%, respectively. As mentioned above, the prevalence of cognitive impairment in China was higher than in other countries. Thus, clinicians and policymakers in China should pay more attention to the control of cognitive impairment in patients with hypertension.

The prevalence varied strikingly among the included studies. Four potential influencing factors were detected: (1) the severity of cognitive impairment: MCI was most prevalent in Chinese patients with hypertension (37.0%) compared with moderate (23.7%) and severe (11.7%) cognitive impairment. (2) the assessment tools for cognitive impairment: the prevalence based on MMSE was 32.0 and 48.7% when MoCA was used, whereas MoCA had a higher sensitivity for MCI (27). (3) recruitment source: our findings revealed that the prevalence of cognitive impairment was higher in hospitalized patients with hypertension than in community-based patients. Hospitalized patients are usually complicated by multiple chronic diseases which could affect their BP and cognitive function. (4) study design: cross-sectional studies (66 studies) reported a higher prevalence than cohort studies (16 studies). Because the association between prevalence and time was neglected for cross-sectional studies, a misestimation of the prevalence was inevitable (28).

4.2 Risk factors for cognitive impairment in Chinese patients with hypertension

In total, 12 risk factors (advanced age, female sex, BMI > 24 Kg/m², lower educational level, single status, complications with diabetes and CHD, higher stages of hypertension, no regular physical activity, higher levels of SBP, Hcy, and IL-6) were associated with an increased risk for the development of cognitive impairment in patients with hypertension.

4.2.1 Risk factors related to the demographic characteristics

The results showed that advanced age was associated with an increased risk of cognitive impairment in Chinese patients with hypertension. A previous review reported that the prevalence of cognitive impairment increased exponentially after the age of 65, nearly doubling every 5 years until the age of 90 (7). Aging accelerated the development of cerebral small vessel lipohyalinosis and atherosclerosis in the circle of Willis, possibly causing chronic cerebral hypoperfusion, which has been recognized as a crucial factor in cognitive impairment (29). Of interest, both advanced age and hypertension share similar mechanisms for cognitive impairment involving oxidative stress and endothelial dysfunction (30, 31). Notably, the majority of the included studies focused on elderly patients, so the age distribution might be a confounder in our study.

As indicated in this study, female patients with hypertension were more likely to suffer from cognitive impairment compared with male patients (OR=1.15). A meta-analysis pointed out that women had a higher risk of progression to AD (RR=1.33) (32). Similarly, another review reported a significantly higher prevalence of non-amnestic MCI in women (33). Holland et al. revealed that female patients with MCI or AD had a greater rate of brain atrophy and clinical decline in comparison to men over a 1-year period, reflecting a faster cognitive decline (34). Moreover, the decline in estrogen levels after menopause would contribute to higher levels of associated pathological substance deposition, resulting in poorer cognitive performance in women (35).

The results of subgroup analysis based on five studies showed that BMI>24 Kg/m² was associated with an increased risk of cognitive impairment in patients with hypertension. A previous meta-analysis showed that both overweight (RR=1.26) and obesity (RR=1.64) in midlife were associated with an increased risk of cognitive impairment (36). Another study indicated that obesity may influence hippocampal long-term potentiation and impair recognition memory, leading to cognitive dysfunction. However, another national longitudinal study based on the elderly population showed that obesity was protective against the development of dementia (HR=0.44) and dementia-related mortality. The correlation between overweight or obesity and cognitive impairment in patients with hypertension needs further investigation.

Consistent with our findings, multiple studies have documented a negative correlation between educational level and the prevalence of cognitive impairment in patients with hypertension (37–40). The results are in line with the brain reserve hypothesis (41), which suggests that individuals with higher levels of education possess a greater cognitive reserve that allows them to better withstand and compensate for the decline in brain function. Meanwhile, higher educational levels may serve as a positive stimulus for the change of brain structure, biochemical metabolism, and complexity of polysynaptic connections, ultimately resulting in a lower risk of cognitive impairment (42).

Our results indicated that patients with hypertension who are single had a higher risk of cognitive impairment compared with married patients. A multicenter cohort study found that single status was associated with a higher risk of hypertension (43). Moreover, Skirbekk et al. (44) revealed that the RR values of cognitive impairment for the unmarried, continuously divorced, and intermittently divorced were 1.73, 1.66, and 1.50, respectively, when taking the continuously married as the reference. In addition, the evidence from France (45), Finland (46), and the United States (47) confirmed the correlation between marital status and cognitive impairment.

4.2.2 Risk factors related to the features of hypertension

In line with our findings (15, 48), higher levels of hypertension were associated with an increased risk of cognitive impairment. In particular, SBP showed a considerable correlation with cognitive function. Launer et al. (49) discovered that each 10 mmHg increase in SBP was associated with an increased risk of cognitive decline. Another longitudinal study published in JAMA found that an elevated baseline SBP of \geq 160 mmHg was associated with a 14% increased risk of cognitive dysfunction during 9 years of follow-up (50). Atherosclerosis, white matter lesions, increased neuritic plaques and tangles, and brain atrophy may be the possible mechanisms (29, 51).

Diabetes and CHD have been identified as risk factors for cognitive impairment in patients with hypertension. Dhikav et al. reported that cardiovascular risk factors, including diabetes, would increase the risk of cognitive impairment (52-54). In a meta-analysis of six prospective studies, diabetes carried a 47% increased risk of dementia (55). On the one hand, diabetes-associated abnormal cerebral angiogenesis and higher capillary density in the central nervous system may speed up the deterioration and leakage of blood vessels during neurodegenerative processes (56). On the other hand, insulin deficiency, the underlying pathology of diabetes, has been linked to higher levels of amyloid beta and increased tau phosphorylation, both of which have been connected to the aberrant metabolism of AD (57, 58). Similar to our findings, Ryuno et al. (59) reported that patients with hypertension and diabetes were more likely to experience cognitive decline than those with hypertension alone. Regarding CHD, a cross-sectional study in Inner Mongolia (60) showed that patients with CHD had a higher risk of developing MCI (OR=3.9) and dementia (OR=6.8). Greater degrees of coronary stenosis may lead to greater gray matter loss in specific brain regions that are relevant to cognitive function (61).

4.2.3 Lifestyle-related risk factors

Engagement in regular physical activity would reduce the risk of cognitive impairment in patients with hypertension. Hamer et al. (62) performed a meta-analysis of 14 prospective studies and revealed that a lack of regular physical activity increased the risk of developing dementia by 39%. Researches have shown that physical activity can increase brain volume (63) and brain-derived neurotrophic factor levels (64). Erickson et al. (65) revealed that aerobic exercise was able to reverse hippocampal volume loss in late adulthood and enhance memory performance. Moreover, multiple meta-analyses have shown that various forms of physical activity can lower BP levels (66–68).

4.2.4 Biomarker-related risk factors

In the present study, we observed an inverse association between Hcy and cognitive function in patients with hypertension. It has been reported that Hcy is involved in the formation and development of hypertension (69). In addition, high levels of Hcy could promote neuronal damage by inducing vascular damage, thus impairing cognitive function (70). Furthermore, higher levels of IL-6 have been associated with poorer cognitive performance (71) and faster cognitive decline (72). Levels of Hcy and IL-6 may serve as biomarkers to reflect the cognitive function of patients with hypertension.

4.3 Comparisons with previous SR

A recent SR conducted by Qin et al. (17) investigated the prevalence of MCI in hypertensive patients. Qin et al. reported that the global prevalence of MCI in patients with hypertension was 30%. Unlike the study conducted by Qin et al., we focused on cognitive impairment (mild to severe) in the Chinese population with hypertension. Because cognitive impairment was prevalent in Chinese hypertensive patients, exploration of the prevalence and risk factors of cognitive impairment in Chinese patients with hypertension would be beneficial for developing effective management strategies. Moreover, we conducted an extensive search and pooled data from 82 studies involving 53,623 patients with hypertension. In addition to the overall prevalence, we further identified 12 risk factors associated with cognitive impairment in Chinese patients with hypertension through detailed subgroup analyses and association analyses. Meanwhile, we assessed the certainty of the evidence using GRADE.

4.4 Limitations

This study had several limitations. First, there was significant heterogeneity among the included studies, and the potential sources of heterogeneity were recruitment source, study design, and cognitive impairment assessment tools according to the meta-regressions. Second, we calculated the value of OR based on the original data without adjusting for the potential discrepancy among the subjects, which resulted in unavoidable confounding effects. Third, because the characteristics of the study population varied, an ecological fallacy may exist.

5 Conclusion

Cognitive impairment was prevalent in Chinese patients with hypertension with a prevalence of 37.6%. The increased prevalence was associated with several demographic characteristics, complicated diseases, no regular physical activity, worse hypertension status, and high biomarker levels. More attention should be paid to the early identification and treatment of patients with hypertension who are at high risk for cognitive impairment in clinical practice.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

References

1. He LI, Wei WR, Can Z. Effects of 12-week brisk walking training on exercise blood pressure in elderly patients with essential hypertension: a pilot study. *Clin Exp Hypertens*. (2018) 40:673–9. doi: 10.1080/10641963.2018.1425416

2. Kanbay M, Demiray A, Afsar B, Covic A, Tapoi L, Ureche C, et al. Role of klotho in the development of essential hypertension. *Hypertension.* (2021) 77:740–50. doi: 10.1161/hypertensionaha.120.16635

3. WHO. Global report on hypertension: The race against a silent killer WHO (2023). Available at: https://www.who.int/publications/i/item/9789240081062

Author contributions

CX: Writing – original draft. DZ: Writing – review & editing. YZ: Writing – review & editing. XLi: Conceptualization, Writing – review & editing. LZ: Conceptualization, Writing – review & editing. XLu: Validation, Writing – review & editing. YG: Data curation, Writing – review & editing. WJ: Investigation, Methodology, Visualization, Writing – review & editing. RJ: Methodology, Writing – review & editing. JL: Methodology, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the National Natural Science Foundation of China (numbers: 82074516 and 82104976) and the Sichuan Province Science and Technology Support Program (number: 2023JDRC0026).

Acknowledgments

The authors gratefully thank Hui Zheng for his help in copyediting the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1271437/ full#supplementary-material

4. Zhang M, Shi Y, Zhou B, Huang Z, Zhao Z, Li C, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a National Survey. *BMJ.* (2023) 380:e071952. doi: 10.1136/bmj-2022-071952

5. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1-7 million adults in a population-based screening study (China peace million persons project). *Lancet.* (2017) 390:2549–58. doi: 10.1016/s0140-6736(17)32478-9

6. Lissek V, Suchan B. Preventing dementia? Interventional approaches in mild cognitive impairment. *Neurosci Biobehav Rev.* (2021) 122:143–64. doi: 10.1016/j. neubiorev.2020.12.022

7. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. *Nat Rev Neurol.* (2018) 14:653–66. doi: 10.1038/s41582-018-0070-3

8. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. Hypertensioninduced cognitive impairment: from pathophysiology to public health. *Nat Rev Nephrol.* (2021) 17:639–54. doi: 10.1038/s41581-021-00430-6

 Emdin CA, Rothwell PM, Salimi-Khorshidi G, Kiran A, Conrad N, Callender T, et al. Blood pressure and risk of vascular dementia: evidence from a primary care registry and a cohort study of transient ischemic attack and stroke. Stroke. (2016) 47:1429–35. doi: 10.1161/strokeaha.116.012658

10. Elias MF, Goodell AL, Dore GA. Hypertension and cognitive functioning: a perspective in historical context. *Hypertension*. (2012) 60:260-8. doi: 10.1161/ hypertensionaha.111.186429

11. Gąsecki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. *Curr Hypertens Rep.* (2013) 15:547–58. doi: 10.1007/s11906-013-0398-4

12. Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure Management for this Global Burden. *BMC Cardiovasc Disord*. (2016) 16:208. doi: 10.1186/s12872-016-0386-0

13. Zhou H, Zhong X, Chen B, Wu Z, Zhang M, Mai N, et al. Interactive effects of elevated homocysteine and late-life depression on cognitive impairment. *J Affect Disord.* (2020) 277:212–7. doi: 10.1016/j.jad.2020.08.022

14. Canavan M, O'Donnell MJ. Hypertension and cognitive impairment: a review of mechanisms and key concepts. *Front Neurol.* (2022) 13:821135. doi: 10.3389/fneur.2022.821135

15. D'Anci KE, Tipton K, Hedden-Gross A, Rouse B, Hermanson L, Fontanarosa J. Effect of intensive blood pressure lowering on cardiovascular outcomes: a systematic review prepared for the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense guidelines. *Ann Intern Med.* (2020) 173:895–903. doi: 10.7326/m20-2037

16. Nugroho P, Andrew H, Kohar K, Noor CA, Sutranto AL. Comparison between the World Health Organization (who) and International Society of Hypertension (Ish) guidelines for hypertension. *Ann Med.* (2022) 54:837–45. doi: 10.1080/07853890.2022.2044510

17. Qin J, He Z, Wu L, Wang W, Lin Q, Lin Y, et al. Prevalence of mild cognitive impairment in patients with hypertension: a systematic review and Meta-analysis. *Hypertens Res.* (2021) 44:1251–60. doi: 10.1038/s41440-021-00704-3

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The Prisma 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev.* (2021) 10:89. doi: 10.1186/s13643-021-01626-4

19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the Jnc 7 report. *JAMA*. (2003) 289:2560–72. doi: 10.1001/jama.289.19.2560

20. Liu LS. 2010 Chinese guidelines for the Management of Hypertension. Chin J Hypertens. (2011) 19:701-43. doi: 10.16439/j.cnki.1673-7245.2011.08.009

21. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of Bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol.* (2012) 65:934–9. doi: 10.1016/j.jclinepi.2011.11.014

22. Rupinski MT, Dunlap WP. Approximating Pearson product-moment correlations from Kennall's tau and Spearman's rho. *Educ Psychol Meas*. (1996) 56:419–29. doi: 10.1177/0013164496056003004

23. Luo X. Association between serum uric acid levels and cognitive dysfunction in elderly patients with hypertension [dissertation/master's thesis]. (2022). China: Nanchang University.

24. Vicario A, Cerezo GH, Del Sueldo M, Zilberman J, Pawluk SM, Lódolo N, et al. Neurocognitive disorder in hypertensive patients. Heart-Brain Study. *Hipertens Riesgo Vasc.* (2018) 35:169–76. doi: 10.1016/j.hipert.2018.01.004

25. Jiménez-Balado J, Riba-Llena I, Abril O, Garde E, Penalba A, Ostos E, et al. Cognitive impact of cerebral small vessel disease changes in patients with hypertension. *Hypertension*. (2019) 73:342–9. doi: 10.1161/hypertensionaha.118.12090

26. Chudiak A, Uchmanowicz I, Mazur G. Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. *Clin Interv Aging.* (2018) 13:1409–18. doi: 10.2147/cia.S162701

27. Jia X, Wang Z, Huang F, Su C, Du W, Jiang H, et al. A comparison of the Minimental state examination (Mmse) with the Montreal cognitive assessment (Moca) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. *BMC Psychiatry*. (2021) 21:485. doi: 10.1186/s12888-021-03495-6

28. Mann CJ. Observational research methods. Research design ii: cohort, cross sectional, and case-control studies. *Emerg Med J.* (2003) 20:54-60. doi: 10.1136/emj.20.1.54

29. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. (2008) 7:476-84. doi: 10.1016/j.cmet.2008.03.010

30. Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J, et al. Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. *Hypertens Res.* (2009) 32:816–20. doi: 10.1038/hr.2009.100

31. Moretti R, Torre P, Antonello RM, Manganaro D, Vilotti C, Pizzolato G. Risk factors for vascular dementia: hypotension as a key point. *Vasc Health Risk Manag.* (2008) 4:395–402. doi: 10.2147/vhrm.s2434

32. Li JQ, Tan L, Wang HF, Tan MS, Tan L, Xu W, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and Meta-analysis of cohort studies. *J Neurol Neurosurg Psychiatry*. (2016) 87:476–84. doi: 10.1136/jnnp-2014-310095

33. Au B, Dale-McGrath S, Tierney MC. Sex differences in the prevalence and incidence of mild cognitive impairment: a Meta-analysis. *Ageing Res Rev.* (2017) 35:176–99. doi: 10.1016/j.arr.2016.09.005

34. Holland D, Desikan RS, Dale AM, McEvoy LK. Higher rates of decline for women and apolipoprotein E Epsilon4 carriers. *AJNR Am J Neuroradiol*. (2013) 34:2287–93. doi: 10.3174/ajnr.A3601

35. Yin ZX, Shi XM, Kraus VB, Fitzgerald SM, Qian HZ, Xu JW, et al. High Normal plasma triglycerides are associated with preserved cognitive function in Chinese oldestold. *Age Ageing*. (2012) 41:600–6. doi: 10.1093/ageing/afs033

36. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a Meta-analysis of prospective studies. *Obes Rev.* (2011) 12:e426–37. doi: 10.1111/j.1467-789X.2010.00825.x

37. Letenneur L, Launer LJ, Andersen K, Dewey ME, Ott A, Copeland JR, et al. Education and the risk for Alzheimer's disease: sex makes a difference. Eurodem pooled analyses. Eurodem incidence research group. Am J Epidemiol. (2000) 151:1064–71. doi: 10.1093/oxfordjournals.aje.a010149

38. Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, et al. Incidence and prevalence of dementia in the cardiovascular health study. *J Am Geriatr Soc.* (2004) 52:195–204. doi: 10.1111/j.1532-5415.2004.52058.x

39. Mehra A, Suri V, Kumari S, Avasthi A, Grover S. Association of Mild Cognitive Impairment and Metabolic Syndrome in patients with hypertension. *Asian J Psychiatr.* (2020) 53:102185. doi: 10.1016/j.ajp.2020.102185

40. Yamamoto K, Akasaka H, Yasunobe Y, Shimizu A, Nomoto K, Nagai K, et al. Clinical characteristics of older adults with hypertension and unrecognized cognitive impairment. *Hypertens Res.* (2022) 45:612–9. doi: 10.1038/s41440-022-00861-z

41. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. *Neurology.* (1993) 43:13–20. doi: 10.1212/wnl.43.1_part_1.13

42. Wang YP, Zhai JB, Zhu F, Zhang WW, Yang XJ, Qu CY. A three-year follow-up study on the transfer of mild cognitive impairment to Alzheimer's disease among the elderly in Taiyuan City. *Chin J Epidemiol.* (2011) 32:105–9. doi: 10.3760/cma.j.issn.0254-6450.2011.02.001

43. Leung CY, Huang HL, Abe SK, Saito E, Islam MR, Rahman MS, et al. Association of Marital Status with Total and cause-specific mortality in Asia. *JAMA Netw Open*. (2022) 5:e2214181. doi: 10.1001/jamanetworkopen.2022.14181

44. Skirbekk V, Bowen CE, Håberg A, Jugessur A, Engdahl B, Bratsberg B, et al. Marital histories and associations with later-life dementia and mild cognitive impairment risk in the Hunt4 70+ study in Norway. *J Aging Health*. (2022) 35:543–55. doi: 10.1177/08982643221131926

45. Helmer C, Damon D, Letenneur L, Fabrigoule C, Barberger-Gateau P, Lafont S, et al. Marital status and risk of Alzheimer's disease: a French population-based cohort study. *Neurology*. (1999) 53:1953–8. doi: 10.1212/wnl.53.9.1953

46. Håkansson K, Rovio S, Helkala EL, Vilska AR, Winblad B, Soininen H, et al. Association between mid-life marital status and cognitive function in later life: population based cohort study. *BMJ*. (2009) 339:b2462. doi: 10.1136/bmj.b2462

47. Liu H, Zhang Y, Burgard SA, Needham BL. Marital status and cognitive impairment in the United States: evidence from the National Health and aging trends study. *Ann Epidemiol.* (2019) 38:28–34.e2. doi: 10.1016/j.annepidem.2019.08.007

48. Iulita MF, Girouard H. Treating hypertension to prevent cognitive decline and dementia: re-opening the debate. *Adv Exp Med Biol.* (2017) 956:447–73. doi: 10.1007/5584_2016_98

49. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. *JAMA*. (1995) 274:1846–51. doi: 10.1001/jama.274.23.1846

50. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. *JAMA*. (1999) 281:438–45. doi: 10.1001/jama.281.5.438

51. Hughes TF, Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia. *Curr Psychiatr Rev.* (2009) 5:73–92. doi: 10.2174/15734000 9788167347

52. Dhikav V, Jadeja B, Kumar AP. Cardiovascular risk factors among older adults with cognitive impairment in primary care. *Int Psychogeriatr.* (2021) 33:837–8. doi: 10.1017/s104161022100082x

53. Dhikav V, Jadeja B, Gupta P. Cognition and cardiovascular comorbidities among older adults in primary Care in West India. *J Neurosci Rural Pract.* (2023) 14:230–4. doi: 10.25259/jnrp_23_2022

54. Dhikav V, Jadeja B, Gupta P. Community screening of probable dementia at primary Care Center in Western India: a pilot project. *J Neurosci Rural Pract.* (2022) 13:490–4. doi: 10.1055/s-0042-1750102

55. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and Meta-analysis. *PLoS One.* (2009) 4:e4144. doi: 10.1371/journal. pone.0004144

56. Prakash R, Johnson M, Fagan SC, Ergul A. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. *PLoS One.* (2013) 8:e56264. doi: 10.1371/journal.pone.0056264

57. Park SA. A common pathogenic mechanism linking Type-2 diabetes and Alzheimer's disease: evidence from animal models. *J Clin Neurol.* (2011) 7:10–8. doi: 10.3988/jcn.2011.7.1.10

58. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-Beta peptide in Alzheimer's disease: review and hypothesis. *Neurobiol Aging*. (2006) 27:190–8. doi: 10.1016/j.neurobiolaging.2005.01.004

59. Ryuno H, Kamide K, Gondo Y, Kabayama M, Oguro R, Nakama C, et al. Longitudinal Association of Hypertension and Diabetes Mellitus with cognitive functioning in a general 70-year-old population: the sonic study. *Hypertens Res.* (2017) 40:665–70. doi: 10.1038/hr.2017.15

60. Yu YX, Bai RY, Yu WL, Guo X, Wu LE. Occurrence status and influencing factors of cognitive dysfunction in population aged 60 and above. *Chin Gen Pract.* (2023) 26:2581–8. doi: 10.12114/j.issn.1007-9572.2023.0004

61. Barekatain M, Askarpour H, Zahedian F, Walterfang M, Velakoulis D, Maracy MR, et al. The relationship between regional brain volumes and the extent of coronary artery disease in mild cognitive impairment. *J Res Med Sci.* (2014) 19:739–45.

62. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med.* (2009) 39:3–11. doi: 10.1017/s0033291708003681

63. Rovio S, Spulber G, Nieminen LJ, Niskanen E, Winblad B, Tuomilehto J, et al. The effect of midlife physical activity on structural brain changes in the elderly. *Neurobiol Aging*. (2010) 31:1927–36. doi: 10.1016/j.neurobiolaging.2008.10.007

64. Komulainen P, Pedersen M, Hänninen T, Bruunsgaard H, Lakka TA, Kivipelto M, et al. Bdnf is a novel marker of cognitive function in ageing women: the Dr's extra study. *Neurobiol Learn Mem.* (2008) 90:596–603. doi: 10.1016/j.nlm.2008.07.014

65. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training increases size of Hippocampus and improves memory. *Proc Natl Acad Sci U S A*. (2011) 108:3017–22. doi: 10.1073/pnas.1015950108

66. Carlson DJ, Dieberg G, Hess NC, Millar PJ, Smart NA. Isometric exercise training for blood pressure management: a systematic review and Meta-analysis. *Mayo Clin Proc.* (2014) 89:327–34. doi: 10.1016/j.mayocp.2013.10.030

67. Edwards JJ, Deenmamode AHP, Griffiths M, Arnold O, Cooper NJ, Wiles JD, et al. Exercise training and resting blood pressure: a large-scale pairwise and network Metaanalysis of randomised controlled trials. *Br J Sports Med.* (2023) 57:1317–26. doi: 10.1136/bjsports-2022-106503

68. Saco-Ledo G, Valenzuela PL, Ruiz-Hurtado G, Ruilope LM, Lucia A. Exercise reduces ambulatory blood pressure in patients with hypertension: a systematic review and Meta-analysis of randomized controlled trials. *J Am Heart Assoc.* (2020) 9:e018487. doi: 10.1161/jaha.120.018487

69. Lu ZH, Li J, Li XL, Ding M, Mao CJ, Zhu XY, et al. Hypertension with Hyperhomocysteinemia increases the risk of early cognitive impairment after first-ever ischemic stroke. *Eur Neurol.* (2019) 82:75–85. doi: 10.1159/000504704

70. Li H, Zhao C, Lin ZJ, Wang L. Analysis of clinical characteristics of cognitive dysfunction and its risk factors in elderly patients with essential hypertension. *Chin J Integr Med Cardio Cerebrovasc Dis.* (2022) 20:565–9. doi: 10.12102/j.issn.1672-1349.2022.03.041

71. Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the Polsenior study. *Immun Ageing*. (2016) 13:21. doi: 10.1186/s12979-016-0076-x

72. Metti AL, Aizenstein H, Yaffe K, Boudreau RM, Newman A, Launer L, et al. Trajectories of peripheral Interleukin-6, structure of the Hippocampus, and cognitive impairment over 14 years in older adults. *Neurobiol Aging*. (2015) 36:3038–44. doi: 10.1016/j.neurobiolaging.2015.07.025